Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS5514379 A
Type de publicationOctroi
Numéro de demandeUS 07/927,068
Date de publication7 mai 1996
Date de dépôt7 août 1992
Date de priorité7 août 1992
État de paiement des fraisCaduc
Autre référence de publicationWO1994003155A1
Numéro de publication07927068, 927068, US 5514379 A, US 5514379A, US-A-5514379, US5514379 A, US5514379A
InventeursRalph Weissleder, Alexei Bogdanov
Cessionnaire d'origineThe General Hospital Corporation
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Hydrogel compositions and methods of use
US 5514379 A
Résumé
Biocompatible, biodegradable, hydrogels are prepared from a backbone bonded to a cross-linking agent. Suitable backbones include proteins and polysaccharides, e.g,, albumin, polymannuronic acid, or polygalacturonic acid. Suitable cross-linking agents include polyvalent derivatives of polyethylene or polyalkylene glycol. These hydrogel compositions may be loaded with diagnostic labels, e.g,, radiopaque, paramagnetic, or superparamagnetic materials, or therapeutic drugs, e.g., chemotherapeutic drugs, antibiotics, or cells that produce therapeutic agents. This invention also relates to methods of use of such hydrogels for imaging during interventional procedures of a patient.
Images(6)
Previous page
Next page
Revendications(17)
What is claimed is:
1. A biocompatible, biodegradable, hydrogel comprising a backbone bonded to a cross-linking agent, wherein said cross-linking agent is a bis-hydroxysuccinimide ester of polyalkylene glycol ("PAG") diacid, bis-hydroxysulfosuccinimide ester of PAG diacid, bis-imidate of PAG diacid, bis-imidazolide of PAG diacid, bis-imidazolide of PAG, bis-halide of PAG, bis-chloranhydride of PAG diacid, bis (n-amino alkyl) of PAG, bis (polyoxyalkylene-bis, or bis benzoxazolide of PAG.
2. The hydrogel of claim 1, further comprising a reporter group loaded into said hydrogel.
3. The hydrogel of claim 2, wherein said reporter group comprises a diagnostic label.
4. The hydrogel of claim 3, wherein said label is detectable by X-ray or magnetic resonance imaging.
5. The hydrogel of claim 4, wherein said X-ray detectable label is an iodine containing compound.
6. The hydrogel of claim 4, wherein said magnetic resonance imaging detectable label is a gadolinium containing compound.
7. The hydrogel of claim 6, wherein said label is gadolinium-diethylenetriamine-pentaacetic acid.
8. The hydrogel of claim 2, wherein said reporter group is entrapped in said hydrogel.
9. The hydrogel of claim 1, wherein said backbone comprises a proteinaceous macromolecule.
10. The hydrogel of claim 9, wherein said backbone comprises from 5 to 50 percent protein by weight of an initial proteinaceous solution.
11. The hydrogel of claim 10, wherein said backbone comprises from 20 to 50 percent protein by weight of said initial solution.
12. The hydrogel of claim 1, herein said backbone is a plasma protein, glycoprotein, polyamino acid homopolymer, polysaccharide derivative, glycosaminoglycan, polyethyleneamine, or polyethylene glycol derivative.
13. The hydrogel of claim 12, wherein said backbone is albumin, polymannuronic acid, or polygalacturonic acid.
14. The hydrogel of claim 12, wherein said polysaccharide derivative is a dextran or starch derivative.
15. The hydrogel of claim 1, wherein said backbone is a recombinant protein.
16. The hydrogel of claim 1, wherein said cross-linking agent is a bis-hydroxysuccinimide ester of polyethylene glycol ("PEG") diacid, bis-hydroxysulfosuccinimide ester of PEG diacid, bis-imidate of PEG diacid, bis-imidazolide of PEG diacid, bis-imidazolide of PEG, bis-halide of PEG, bis-chloranhydride of PEG diacid, bis (n-amino alkyl) of PEG, bis (polyoxyethylene-bis ), or bis benzoxazolide of PEG.
17. A therapeutic composition comprising
a biocompatible, biodegradable hydrogel comprising a backbone bonded to a cross-linking agent, wherein said cross-linking agent is a bis-hydroxysuccinimide ester of polyalkylene glycol ("PAG") diacid, bis-hydroxysulfosuccinimide ester of PAG diacid, bis-imidate of PAG diacid, bis-imidazolide of PAG diacid, bis-imidazolide of PAG, bis-halide of PAG, bis-chloranhydride of PAG diacid, bis (n-amino alkyl) of PAG, bis (polyoxyalkylene-bis), or bis benzoxazolide of PAG,
a diagnostic label, and
a therapeutic drug, wherein said diagnostic label and said therapeutic drug are both loaded into said hydrogel.
Description

This invention was made with Government support under Contract #RO1-CA-54886 awarded by the National Institutes of Health. The Government has certain rights in the invention.

BACKGROUND OF THE INVENTION

This invention relates to biocompatible and biodegradable hydrogel compositions, and to methods of use of such hydrogels for imaging during interventional procedures of a patient.

A variety of radiologic imaging techniques are available that allow the operator to diagnose disease and monitor therapeutic interventional procedures such as embolizations or abscess drainages. Whereas many imaging techniques are useful for the diagnosis of disease, e.g., ultrasound, scintigraphy, positron emission tomography ("PET"), single photon emission computed tomography ("SPECT"), X-ray, computed tomography ("CT"), and magnetic resonance imaging ("MRI"), only X-ray (fluoroscopy, computed tomography) and MRI are frequently used to monitor therapeutic interventions.

Therapeutic interventional imaging procedures are performed primarily in the fields of interventional radiology ("IR") and minimal invasive therapy ("MIT"). Both fields have become important adjuncts to traditional surgical techniques and have even replaced some classical surgical techniques because of their lower invasiveness, shorter convalescence, and similar or equal effectiveness. Well established IR procedures include abscess drainage, tumor embolizations, and biopsies. IR procedures are always performed in conjunction with radiological imaging, whereas MIT procedures are more surgical in nature and use imaging only when it is necessary to visualize the interventional devices used during the procedure.

Therapeutic drugs are often used in conjunction with procedures such as MIT and IR, and the concentration of these drugs in a patient is indicative of the efficiency of treatment. Therefore, it is important to accurately monitor the delivery, concentrations, and release, of these drugs in vivo, particularly after MIT, IR, and surgery. However, such drugs are typically not detectable by conventional CT or MR imaging techniques, because they do not contain radiopaque or magnetically active labels ("contrast agents").

Contrast agents were originally developed for use with diagnostic imaging techniques to further improve the diagnosis of disease. However, these agents have no therapeutic effect in interventional imaging procedures. For example, CT and MR contrast agents designed for intravascular use are water-soluble and are usually small molecules containing radiopaque, paramagnetic, or superparamagnetic elements. Such contrast agents are primarily administered intravascularly to facilitate diagnosis by selectively altering the signal arising in normal or abnormal tissues. Certain contrast agents also include particulate materials for gastrointestinal (oral or rectal) use. However, these gastrointestinal agents are undesirable for interventional use, because they are hyper-osmolar and/or toxic if administered intravascularly or intracorporally.

Known diagnostic agents for human use, e.g., contrast agents for X-ray imaging, contain labels, e.g., iodine or barium, which are covalently or non-covalently bonded to other atoms to make them biocompatible. Diagnostic MR contrast agents usually contain a paramagnetic label, e.g., gadolinium ("Gd"), dysprosium, iron, or manganese, or a superparamagnetic label, e.g., iron oxide. These otherwise toxic labels are made biocompatible by chelating the ions, e.g., with diethylenetriamine-pentaacetic acid ("DTPA") to form Gd-DTPA, or by coating particulates with a polymer, e.g., with dextran or arabino-galactan, to form iron oxides.

For example, Hall, PCT patent application 89/11874 (1990), describes contrast preparations containing a biodegradable, porous particulate substrate, e.g., Sepharose™ or polystyrene, with surface bound paramagnetic labels, e.g., Gd-DTPA, with no significant release of the label when administered. The substrate may be a hydrogel, polyglycolic acid, cross-linked protein, and the like. These water-insoluble preparations may be used as MR contrast agents, e.g., for the gastrointestinal tract or the vascular system.

Bligh et al., Magn. Reson. Med., 17:516-532 (1991), describes the use of soluble (e.g., dextran) and insoluble (e.g., starch or cellulose) polysaccharide-linked Gd-DTPA contrast agents for MR imaging. The insoluble polysaccharides are not covalently linked to each other by a cross-linking reagent. Soluble agents were administered intravenously and insoluble agents were fed orally without injections into the blood stream.

Unger, PCT patent application 91/15713 (1991), describes aqueous solutions of polymers as contrast media for MRI. These media comprise biocompatible polymers, e.g., polyethylene glycols, polyoxyethylene glycols, or polymers of galacturonic or mannuronic acid, in admixture (not covalently bound) with, e.g., paramagnetic or superparamagnetic agents. If cross-linked, these contrast media may be water-insoluble.

In addition, Gd-DTPA labeled gel "tissue phantoms," i.e., artificial in vitro models of tissues, made of polyacrylamide, agarose, glutaraldehyde cross-linked albumin gels, or styrenes, have been described for experimental MR imaging or other uses such as magnetic separations. However, these agents are not desirable or suitable for human use because of their local or systemic toxicity.

Inada et al., U.S. Pat. No. 4,814,098, describes the use of a ferromagnetic material bound to a physiologically active substance, e.g., an enzyme, through a PEG derivative linker. These water-soluble colloidal solutions are used for magnetic separation of physiologically active substances.

Some radiopaque particulate materials have also been proposed for embolization purposes. These materials exhibit a strong local toxic reaction, and may elicit an immunogenic response upon repeated administration or may not be biodegradable. Furthermore, these agents do not contain paramagnetic labels and are unlikely to be useful for drug delivery estimation because of the large quantities of radiopaque materials required for CT, e.g., 10 to 40 percent of the particulate is iodine.

For example, radiopaque hylan for embolization contains a combination of hylan, e.g., hyaluronan or hyaluronate (cross-linked with vinyl-sulfone), tantalum, microscrystalline cellulose, hexamethonium chlorine, and thrombin. Additional embolization materials include radiopaque non-biodegradable hydrogel microspheres based on poly (2-hydroxyethyl) methacrylate ("PHEMA")/iothalamic or iopanoic acid as described by Jayakrishnan et al., J. Biomed. Mat. Res., 25:993-1004 (1990). These microspheres were non-biodegradable over 6 month interval when implanted into rats.

Other embolization materials include Sephadex™ and Sepharose™, which are polysaccharides cross-linked with halogenated compounds such as epichlorohydrin. A method for obtaining biodegradable Sephadex, e.g., partially oxidized Sephadex, is described in Torchilin et al., J. Biomed. Mater. Res., (1977). Sephadex microparticles have also been labelled with ferromagnetic iron oxide and used for immobilizing enzymes and targeting the microparticles by applying an external magnet.

Certain hydrogels and microspheres have also been used for drug delivery. For example, biodegradable polymer systems have been described for the slow release of therapeutic drugs. Chemotherapeutic drugs have been bound to or incorporated into a variety of slow release systems including fibrinogen microspheres, albumin, gelatin, methylene diisocyanate cross-linked collagen, polylactic acid spheres, polysaccharides such as dextran and starch, or polyamino acids. All of these agents are expected to have high local tissue toxicity, be immunogenic in vivo, or be non-detectable by an imaging system.

For example, Feijen, U.S., Pat. No. 5,041,292, describes a biodegradable hydrogel for drug delivery systems which consists of proteins cross-linked with polysaccharides, e.g., heparin, heparan, or chondroitin, to form microspheres loaded with a drug using a solvent extraction technique.

SUMMARY OF THE INVENTION

The invention features biodegradable, biocompatible, hydrogels for imaging during interventional procedures, e.g., MIT and IR, to monitor and guide these procedures. These hydrogels are water-insoluble yet water-swellable, i.e., they can absorb water. This water absorption is beneficial for MR imaging of these compounds, because this imaging technique measures the relaxivities of the protons in the water.

These hydrogels include a polymeric backbone insolubilized by cross-linking agents which allow the hydrogels to absorb large amounts of water, which makes them well suited for proton relaxation imaging, e.g., MRI. The hydrogels also may be loaded with a diagnostic label detectable by CT or MR imaging techniques, and/or with a therapeutic drug, and are administered intravascularly as well as by implantation. The diagnostic labels and/or therapeutic drugs can be loaded into the hydrogel during synthesis, or afterwards, e.g., by diffusion into the hydrogel compositions.

The hydrogel compositions disclosed herein have high biocompatibility, e.g., they do not cause severe side effects, and low immunogenicity of both the primary materials and their degradation products, which allows repeated administration. In addition, these hydrogels when loaded with labels or drugs exhibit minimal or nonexistent local or systemic toxicity, compared to the potentially toxic labels or drugs with which they are loaded. At the same time, despite being cross-linked, these hydrogels are rapidly degraded in vivo, e.g., through enzymatic degradation, into non-toxic compounds within a few days to weeks.

The invention features a biocompatible, biodegradable, hydrogel including a backbone bonded to a cross-linking agent of the formula

R1 --O-- (CH2)n --O!m --R2,

wherein each R1 and R2, independently, is an organic group, at least one of R1 and R2 being capable of reacting with the backbone, n is 2 or 3, preferably 2, inclusive, and m is an integer from 10 to 200, and preferably from 50 to 150, inclusive. R1 and R2 may be the same or different.

These hydrogel compositions can be loaded with a reporter group, e.g., a diagnostic label or therapeutic drug, that may be entrapped in or covalently bonded to the hydrogel. Such labels are detectable by various imaging techniques, e.g., X-ray imaging (e.g., an iodine containing compound), which includes fluoroscopy and CT scanning, or magnetic resonance imaging (e.g., a gadolinium containing compound, e.g., Gd-DPTA).

The reporter group may also be a cell, or cell line, loaded into the hydrogel where the cell can grow and produce a therapeutic agent, e.g., an anti-cancer agent, antibiotic, cardiovascular agent, analgesic, central nervous system-active agent, hematopoietic agent, hemostasis agent, hormone, pro-hormone, protein, or an enzyme.

When the backbone includes a proteinaceous macromolecule, it includes at least 5 percent, and preferably from 20 to 50 percent, by weight of the proteinaceous macromolecule of an initial protein solution. When the backbone includes a polysaccharide derivative, it includes at least 1 percent, and preferably from 2 to 5 percent, by weight of the polysaccharide derivative of an initial polysaccharide derivative solution. The backbone may also include a synthetic polymer.

The backbone may be a plasma protein, e.g., albumin, tissue protein, e.g., collagen, glycoprotein, recombinant protein, polyamino acid, e.g., polylysine, carboxylated polysaccharide, glycosaminoglycan, dextran derivative, starch derivative, polyethyleneimine, or polyethylene glycol derivative. The backbone is preferably albumin, polymannuronic acid, or polygalacturonic acid.

The cross-linking agent may be, e.g., a polyvalent derivative of polyalkylene glycol or polyoxyethylene glycol, and is preferably a derivative of polyethylene glycol, polypropylene glycol, or copolymers thereof.

The invention also features a method for preparing these hydrogels by reacting the backbone with the cross-linking agent to produce the hydrogel. Certain backbones may first be derivatized to make them reactive, or more reactive. The invention also features a method of loading the hydrogel with a reporter group, e.g., during or after synthesis of the hydrogel.

The invention further features a method for providing an image, e.g. X-ray or MR image, of an internal region of a patient by administering to the patient a diagnostically effective amount of a labeled hydrogel, and scanning the patient using an imaging technique that can detect the label to obtain an image of the region. A "diagnostically effective amount" of the hydrogel is an amount that will provide an image of the hydrogel in the patient.

The invention also features a method for diagnosing the presence of diseased tissue in a patient by administering to the patient a diagnostically effective amount of a labeled hydrogel, and scanning the patient using an imaging technique that can detect the label to obtain a visible image of any diseased tissue in the patient.

In addition, the invention features a method for treating diseased tissue, e.g., cancer, infection, deficiency states, or hemorrhage, in a patient by administering to the patient a therapeutically effective amount of a hydrogel loaded with a therapeutic drug, cell that produces a therapeutic drug, and/or label, and scanning the patient using an imaging technique that can detect the label to obtain a visible image of any diseased tissue in the patient. A "therapeutically effective amount" of the hydrogel is an amount that will provide a therapeutic benefit to the patient. The treatment is effected by the release of pro-drugs, therapeutic drugs, cells, proteins, etc. from the hydrogel or by the hydrogel physically interrupting blood flow after intravenous administration.

The invention also features a method for estimating the concentration of a drug delivered to a patient from a hydrogel loaded with a drug and/or a label, by administering a therapeutically effective amount of the hydrogel to the patient, scanning the patient using an imaging technique that can detect the label to obtain an image of the label, calculating the release rate of the label, determining a correlation between the label release rate and the concentration of the drug in the hydrogel, and estimating the concentration of the drug delivered to the patient based on the correlation.

The invention further features a method for embolizing a given region in a patient comprising injecting an effective amount of a hydrogel loaded with a label and/or a drug intravascularly into the region to be embolized. The embolized region then may be scanned using an imaging technique that can detect the label to obtain an image of the embolized region.

Furthermore, the invention features a method for delivering a drug to a patient over an extended period of time by administering a therapeutically effective amount of a hydrogel loaded with a drug, label, and/or cell to the patient.

The invention also features a method for providing an image of an interventional device in an internal region of a patient in real time by coating the device with a labeled hydrogel, using the device in an internal region in the patient, and scanning the patient using an imaging technique that can detect the label to obtain an image of the device. The invention also covers interventional devices coated with a labeled hydrogel.

The term "derivative" as used herein means a compound whose core structure is the same as or closely resembles that of a parent compound, but which has a chemical or physical modification, such as different or additional side groups; the term includes copolymers of parent compounds.

The term "loaded" when used herein to describe a hydrogel encompasses any form of incorporation (covalent or non-covalent) of the reporter group into the hydrogel of the invention. The reporter group may be entrapped within the hydrogel matrix or may be covalently bonded to either the backbone or the cross-linking agent of the hydrogel.

The term "reporter group" encompasses diagnostic labels, e.g., paramagnetic or superparamagnetic compounds such as Gd-DTPA or iron oxides, radiopaque compounds, such as iodine compounds; therapeutic drugs, such as antibiotics, hormones, anti-cancer compounds, cardiovascular agents, enzymes, analgesics, central nervous system-active drugs; and cells producing therapeutic agents, e.g., insulin.

The term "imaging" includes any technique that can diagnose disease in a human or animal patient. The term includes X-ray, CT, MR imaging, etc. The term imaging also includes practicing the technique on a patient.

Other features and advantages of the invention will be apparent from the following description of the preferred embodiments in conjunction with the claims and the drawings.

BRIEF DESCRIPTION OF THE DRAWING

Figs. 1a and 1b are schematic diagrams of a hydrogel consisting of a backbone, a cross-linking agent, and at least one label. FIG. 1a shows an entrapped label, whereas FIG. 1b shows a covalently bound label.

FIGS. 2a-c are graphs showing the degradation of hydrogel compositions of the invention under varying conditions.

FIG. 3 is a graph showing the release of gadolinium and rhodamine (covalently bonded) from a hydrogel composition in an in vitro system.

FIG. 4 is a graph showing the release of gadolinium and 111-Indium (both non-covalently bonded) from a hydrogel composition in an in vitro system.

FIG. 5 is a graph showing the correlation between the release of 111-In-DTPA and Gd-DTPA from a hydrogel composition in vitro.

FIG. 6 is a graph showing the release of a therapeutic drug model (isosulfan blue) from a hydrogel composition (non-covalently bonded) in an in vitro system.

FIG. 7 is a series of MR images taken at (from left to right) 2, 5, and 10 days, of a rat implanted with a hydrogel disk (arrow), showing the release of a label over time.

FIG. 8 is a photo of the left kidney (arrow) and tumor of a rabbit which are embolized with a hydrogel composition of the invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

As shown in FIG. 1, the hydrogel compositions include a backbone (shown as ) a cross-linking agent (shown as --572 ), and at least one reporter group, e.g., a label (shown as ▴). The preferred components are described separately below.

Backbone

The hydrogel composition includes any one of a variety of biocompatible, degradable, and metabolizable organic or inorganic backbones. The backbone is preferably a hydrophilic macromolecule with multiple side groups available to react with the cross-linking agent.

The concentration of the backbone in an initial reaction solution (backbone solubilized in water) has to be sufficiently high to allow extensive cross-linking and subsequent hydrogel formation. If the concentration of the backbone is too low, no hydrogel will form, although cross-linking may still occur to some extent.

Minimum concentrations for protein-based backbones are typically at least 5.0% protein by weight in the reaction solution, i.e., solubilized in 95% water, but may vary for different backbones. Preferred protein hydrogels contain 20-50% protein in the initial solution.

Minimum concentrations for polysaccharide backbones also depend on the structure and molecular weight of the specific backbone, but for carboxylated polysaccharides, starting solutions should be at least 1.0% of the polysaccharide. Preferred polysaccharide hydrogels contain 2-5% polysaccharide by weight in the initial solution.

The following list summarizes backbones suitable for use in the present invention:

Proteinaceous backbones

Individual proteins

albumins

globulins

extracellular matrix proteins (e.g. collagen, fibronectin)

fibrinogen

fibrin

thrombin

Plasma protein mixtures

plasma

plasma fractions

Glycoproteins

Chemically modified proteins

Recombinant proteins or peptides

Sugar containing backbones

Carboxylated polysaccharides

polymannuronic acid

polygalacturonic acid

polyguluronic acid

Aminated polysaccharides

glycosaminoglycans

Activated polysaccharides

dextran derivatives

starch derivatives

Synthetic backbones

Polylysines

Polyethyleneimines

Polyethylene glycol and its derivatives

The term "chemically modified protein" means a protein molecule in which at least one chemical bond is produced or eliminated within the molecule. The term includes proteins which are, e.g., acylated, glycosylated, deglycosylated, oxidized, reduced, fractionated into peptide fragments, or phosphorylated.

The most preferred backbones are albumin or carboxylated polysaccharides, e.g., polymannuronic or polygalacturonic acids, because of their degradation in vivo, known tissue compatibility, and relatively low cost.

Cross-linking Agents

As shown in FIG. 1, the cross-linking agents form covalent bonds with either two backbones, one backbone, or one backbone and a reporter group. The generic formula of a hydrophilic cross-linking agent for use in the hydrogel compositions of the invention is:

R1 --O-- (CH2)n --O!m --R2 

Wherein each R1 and R2, independently, is an organic group, at least one of R1 and R2 being capable of reacting with said backbone, n is 2 or 3, inclusive, and m is an integer from 10 to 200, inclusive. R1 and R2 can be the same or different organic groups. Preferably n is 2, and m is preferably from 50 to 150. These cross-linking agents are easily hydrated, decrease the toxicity of the backbone, and decrease the immunogenicity of the hydrogel compositions. The molecular structures of suitable R1 and R2 groups are apparent from the following list of cross-linking agents.

Preferred cross-linking agents for use in the hydrogel compositions are highly reactive, polyvalent derivatives of polyalkylene glycol (PAG). For example, when n is 2, PAG is polyethylene glycol; when n is 3, PAG is polypropylene gycol. The cross-linking agents also include copolymers of PAG, e.g., polyethylene glycol/polypropylene glycol block copolymers ("Pluronics"). As used herein, the term "polyvalent" means that the agent has two or more reactive organic groups to bind to the side groups of the hydrogel backbone, i.e., R1 and R2.

The most preferred cross-linking agents are derivatives of polyethylene glycol (PEG). PEG itself is not a preferred cross-linking agent, because it will not readily react with the backbones.

Cross-linking agents suitable for use in the hydrogel compositions are summarized in the following list:

Polyethylene or polyoxyethylene glycol derivatives

bis-hydroxysuccinimide ester of PEG diacid

bis-hydroxysulfosuccinimide ester of PEG diacid

bis-imidate of PEG diacid

bis-imidazolide of PEG diacid

bis-imidazolide of PEG

bis-halide (Cl, Br, F) of PEG

bis-chloranhydride of PEG diacid

bis (n-amino alkyl) of PEG

bis (polyoxyethylene-bis n-amino-alkyl!)

bis benzoxazolide of PEG

Polyalkylene glycol derivatives

bis-hydroxysuccinimide ester of PAG diacid

bis-hydroxysulfosuccinimide ester of PAG diacid

bis-imidate of PAG diacid

bis-imidazolide of PAG diacid

bis-imidazolide of PAG

bis-halide (Cl, Br, F) of PAG

bis-chloranhydride of PAG diacid

bis (n-amino alkyl) of PAG

bis (polyoxyalkylene-bis n-amino-alkyl!)

bis benzoxazolide of PAG

Diagnostic Labels

The hydrogel compositions may be loaded with a diagnostic label either during synthesis of the hydrogel, or afterwards, e.g., by diffusion into the stable hydrogel composition. These labels either may be entrapped in the hydrogel matrix without any chemical bond, or they may be bonded, non-covalently or covalently, to the backbone or cross-linking agent of the hydrogel.

The release kinetics of the label are ultimately determined by the type of binding of the label and this invention covers the use of different release kinetics for different applications. For example, if fast release of a label is desired it should be non-covalently entrapped; when slow release is desired, e.g., when more toxic labels are used, the label should be covalently bonded.

The following list summarizes diagnostic labels suitable for loading into the hydrogel compositions. This list is exemplary, and any variety of diagnostic label could be used. As used herein, DTPA is diethylene triaminepentaacetic acid; DOTA is 1,4,7,10-tetraazacyclododecane-N,N,N',N'"-tetraacetic acid; EDTA is ethylenediaminetetraacetic acid; DO3A is 1,4,7,10-tetraazacyclododecane-N,N',N"-triacetic acid; NOTA is 1,4,7-triazacyclononane-N,N',N"-triacetic acid; TETA is 1,4,8,11-tetraazacyclotetradecane-N,N',N",N'"-tetraacetic acid; and HBED is hydroxybenzylethylene-diamine diacetic acid.

Radiopaque labels (for X-ray imaging)

Inorganic and organic iodine compounds

(e.g. diatrizoate, non-ionic dimers)

Radiopaque metals and their salts

(e.g. Ag, Au)

Other radiopaque compounds

(e.g. Ca salts, Ba salts)

Paramagnetic labels (for MR imaging)

Gd-DTPA and its derivatives

Gd-DTPA-protein

Gd-DTPA-poly-L-lysine

Gd-DTPA-dextran

Gd-DTPA-polymers

Other paramagnetic complexones

Gd complexones

(e.g. Gd-DOTA, Gd-EDTA, Gd-DO3A, Gd-NOTA, Gd-TETA)

Mn complexones

(e.g. Mn-DPDP )

Fe complexones

(e.g. Fe-HBED)

Dy complexones

Cu complexones

Eu complexones

Er complexones

Cr complexones

Ni complexones

Co complexones

Superparamagnetic labels (for MR imaging)

Magnetites

Superparamagnetic iron oxides

Monocrystalline iron oxides

Other (for MR imaging)

Spin-labels

(e.g. nitroxyl labels)

"Complexones" are chelates of metal ions with paramagnetic properties, but greatly reduced toxicity when compared to the free metal ions.

The amount of label to be loaded into the hydrogel depends on the nature of the label. For gadolinium containing compounds, about 15 mg of Gd-DTPA-BSA/ml of hydrogel have been found to provide a clear MR image. For iodinated compounds, e.g., Hypaque™, about 100 to 400 mg of iodine/ml of hydrogel have been found to provide a clear X-ray image.

Therapeutic Drugs

A variety of therapeutic drugs also may be loaded into the hydrogel compositions of the invention, either in addition to a diagnostic label, or in place of such a label. The drugs may be loaded into the hydrogel compositions in the same way as described above for the diagnostic labels, i.e., by entrapment or chemical bonding. The following list of therapeutic drugs is exemplary, but is not intended to be exhaustive:

Chemotherapeutic agents

Antibiotic agents

Cardiovascular agents

Analgesics, CNS drugs

Drugs affecting hematopoiesis and hemostasis

Hormones, prohormones

Proteins (including albumin)

Enzymes

Cells producing therapeutic agents (e.g. insulin)

Solutes (glucose, NaCl, etc)

The rate of release, or release kinetics, of these drugs from the hydrogel compositions once administered to a patient are a determined by a variety of factors including the size of the drug molecules, the specific backbone and cross-linking agents used to prepare the hydrogel, and the type of binding of the drug. This invention covers the use of different drug release kinetics for different applications. For example, to achieve plasma saturation quickly, a drug may be entrapped (see Example 4, below). If slower drug release is required, covalent bonding is preferred (see Example 2, below).

The amount of drug to be loaded into the hydrogel depends on the nature of the drug. For a chemotherapeutic drug, e.g., doxorubicin, and antibiotics, e.g., gentamicin, about 10 mg of the drug/ml of hydrogel have been found to be effective. The drug loaded hydrogels are administered to patients via a catheter in amounts ranging from about 0.1 to 00 ml of the hydrogel, preferably 2 to 10 ml.

Biological effects

The biological effects of the hydrogel compositions in a patient depend on the manner of administration, e.g. intravascular, implantation, or intracavitary, and the type of reporter group, e.g., label or drug, incorporated into the composition. Implanted hydrogel compositions are degraded in vivo (FIG. 2a-c) and in vitro when incubated with macrophages (not shown). In either case, as the hydrogel composition is degraded, it releases the loaded reporter group at a predetermined rate based on the known rate of degradation. These observations are confirmed by experiments which show that the preferred hydrogel compositions are degraded by proteases, such as trypsin (FIG. 2a). The degradation is a function of the amount of cross-linkage, the concentration of the backbone (see below), and the activity of the proteases.

Initial data suggest that degradation is a process which proceeds from the surface of the hydrogel particles. Cleaved fragments are presumed to be eliminated by the kidneys as is known to occur for PEG fragments with molecular weights of 4,000 daltons. In addition, the reporter group may be released from the hydrogel over time even if the hydrogel is not degraded.

The tissue response to implanted hydrogel compositions at the implantation sites is mild, i.e., less than that described by other investigators for wound dressings, e.g., Yoshioka, et al., Int. J. Pharm., 8:131-141 (1981). When the preferred hydrogel compositions are administered intravascularly, the protective effects of PEG derivatives are believed to elicit only a minimal, if any, immunogenic response.

Use of the Hydrogel Compositions

The hydrogel compositions have a variety of medical and biomedical applications. The applications and usages are described briefly below and are discussed in more detail in the following specific examples.

The compositions may be used for intravascular embolization while imaging or for chemo-embolization; for drug delivery, e.g., antibiotic delivery during abscess drainages, slow release of chemotherapeutic drugs, pro-drug or enzyme delivery, and hormone replacement therapy; for estimating drug delivery by imaging based on the correlational dependence of the release of a therapeutic drug and the release of a diagnostic label; for MR imaging markers without magnetic distortion, e.g., surface skin markers or intracorporal markers for radiotherapy; for coating medical devices, e.g., as a lubricious coating for catheter systems, to improve the biocompatibility of interventional devices, and to visualize interventional devices with imaging techniques; for forming biodegradable devices for interventional use and implantation, e.g., a biodegradable vena cava filter with and without diagnostic labels, or a biodegradable substrate for stent or catheter synthesis; for immobilizing cells in the hydrogels for injection or implantation into a patient and imaging; and as a contrast agent for intravascular use.

EXAMPLES 1. Synthesis of a Bivalent Cross-linking Agent

Described here is the synthesis of bis(N-hydroxy-succinimidyl)polyethylene glycol disuccinate. This activated cross-linking agent is capable of reacting with amino groups of a suitable backbone.

Preparation of PEG-3350-disuccinate

60 g (17.9 mmol) of PEG-3,350 (Sigma Chemical Co, St. Louis, Mo.) was dissolved in 300 ml of dioxane in a 2-necked 1 L flask and heated to 90° C. 18 g of succinic anhydride (5-fold molar excess) and 0.5 g of N,N'-dimethylaminopyridine were dissolved in the same solution. The flask was equipped with a refluxing column and inlet for nitrogen. The mixture was slowly purged with nitrogen and heated to 100° C. for 8 hours. The mixture was cooled, concentrated three-fold by rotary evaporation, filtered on a glass-fritted filter (20-30 μm) to remove succinic acid, and evaporated to dryness. The residue was dissolved in a minimal amount of ethylacetate (50 ml) and added to 300 ml of ethyl ether. A precipitate formed at 4° C. and was separated, and the procedure was repeated. The thus purified precipitate was dissolved in 100 ml of water and passed through a column containing 25 g of AG 50W-X8 resin (Bio-Rad, Melville, N.Y). The flow-through was diluted 5-fold with water and lyophilized. The yield was 50 g PEG-3350-disuccinate, or about 78%.

Synthesis of bis-hydroxysuccinimide ester of PEG disuccinate

30 g of the dry solid PEG-3350-disuccinate from the previous step was dissolved in 100 ml of tetrahydrofuran and added to 4 g of N-hydroxysuccinimide (2-fold molar excess). After solubilization, 3.8 g (1.1 molar excess) of dicyclohexycarbodiimide was added, the solution was stirred for 3 hours, cooled to 4° C., and filtered at room temperature to remove insoluble dicyclohexylurea. The filtrate was evaporated to dryness by rotary evaporation, re-dissolved in a minimal amount of methanol (20 ml) and filtered again. Then 300 ml of diethyl ether was added and the precipitate was collected by filtration. This procedure was repeated once. The yield was 23 g of bis-hydroxy-succinimide ester of PEG disuccinate, or about 72%.

2. Synthesis of Paramagnetic Cross-linked Protein Hydrogel

Synthesis of Gd-DTPA-albumin

Gd-DTPA was attached to bovine serum albumin (BSA) using a method similar to those previously described in Frejcarek et al., Biochem. Biophys. Res. Comm., 77:581-586 (1977) and Hnatowich et al., J. Immunol. Meth., 65:147-157 (1983). Briefly, 2 g of BSA (Sigma) were dissolved in 100 ml of bicarbonate buffer at pH 9.1, and an aliquot of cyclic DTPA anhydride ("cDTPAA") (Pierce) was added. After two hours, free DTPA was removed by ultrafiltration with a YM3 filter (Amicon, Beverly, Mass.). Transchelation of BSA-DTPA was performed with 0.1M gadolinium citrate. The reaction product, Gd-DTPA-BSA, was purified by further ultrafiltration, and then lyophilized.

Formation of a paramagnetic hydrogel

1400 mg BSA and 10 mg of Gd-DTPA-BSA were dissolved in 7 ml of phosphate buffered normal saline (pH 8.5). Then 460 mg of the cross-linking agent bis-hydroxysuccinimide ester of PEG disuccinate (Example 1) was dissolved in 600 μl DMSO at 60° C. The cross-linking agent was mixed with the BSA solution and reacted at room temperature for 15 minutes during which gelation occurred. Thereafter, the hydrogel composition was removed and washed in 6 L of 0.9% NaCl for 24 hours to remove DMSO and unreacted products. As an alternative to BSA, equivalent amounts of human blood or human IgG were also used for cross-linking.

Formation of paramagnetic hydrogel with a therapeutic drug

Five ml of a 20% BSA/Gd-DTPA-BSA solution was prepared as described above. One μg of rhodamine X (as a model of a therapeutic drug) (Molecular Probes, Oregon) in 20 μl DMSO was added to an 2.5 ml aliquot of this solution. One mg of doxorubicin was added to the other 2.5 ml aliquot. Both samples were then mixed with 230 mg of the cross-linking agent dissolved in 300 μl DMSO, each at 60° C. After reaction at room temperature for 15 minutes, paramagnetic hydrogels with the therapeutic drug models were removed and washed in 6 L of 0.9% NaCl for 24 hours to remove DMSO and unreacted products. This material is preferred for embolization.

3. Synthesis of Paramagnetic Cross-linked Polysaccharide Hydrogel

A polysaccharide-based hydrogel cross-linked with a bivalent PEG derivative was synthesized as follows. A 4% sodium alginate (Sigma) solution was prepared and its pH adjusted to 5.0 using 1N HCl. 100 mg of 15 mM of N-hydroxysulfosuccinimide (Pierce) was added while re-adjusting the pH to 5.0 to activate available carboxyl groups on the polymannuronic acid backbone. 100 mg of 1-ethyl-3-(dimethyl-aminopropyl)carbodiimide hydrochloride was dissolved in 100 μl H2 O and added to the above solution. The mixture was allowed to react for 10 minutes at room temperature. The pH of the solution was then raised to 8.5 with 5N NaOH and 100 μl of concentrated polyoxyethylene-bis (6-aminohexyl) (Sigma) or bis(polyoxyethylene-bis 3-amino-2-hydroxy-propyl) was added. After gelation, the hydrogel was dialyzed in 0.9% NaCl to remove by-products of the reaction.

4. Synthesis of Radiopaque Cross-linked Hydrogel

Two ml of BSA (40% with 10 mg of Gd-DTPA-BSA) was mixed with 2 ml of aqueous sodium diatrizoate 76%, which contains approximately 37% organically bound iodine. The pH was adjusted to 8.5 with bicarbonate, and reacted with 200 mg cross-linking agent in 200 μl DMSO. The hydrogel was then implanted into a rat. No adverse side effects were observed.

5. Degradation of Paramagnetic Hydrogel

Hydrogels with different concentrations of albumin backbone (40%, 30%, 20%, 15%, 10%) were synthesized as described in Example 2. Equivalent amounts of the hydrogel samples were then incubated at different concentrations of trypsin (0.05% =1:1, 1:5, 1:10) (FIG. 2a), and at different temperatures (37° C., 20° C. 4° C.) (FIG. 2b), to determine the degradation of the hydrogel. These experiments unequivocally demonstrate that degradation occurs in vitro and that this degradation is dependent on the activity of the protease. As shown in FIG. 2a, the highest concentration of trypsin (1:1) caused the fastest degradation. FIG. 2b shows that degradation increases with temperature. Finally, FIG. 2c shows that degradation is fastest with the lowest concentration (10%) of the albumin backbone in the hydrogel composition.

6. Correlational Estimation of Drug Concentration

The following experiments were conducted to show that drug release kinetics from the hydrogel can be calculated by knowing the release kinetics of diagnostic, e.g., radiographic, labels. The hydrogels used in these experiments were similar to those described in Example 2.

Covalent drug bonding

The hydrogel compositions contained Gd-DTPA (diagnostic T1 label) and rhodamine (drug model) covalently bound to an albumin backbone. The hydrogels were extensively washed in saline to remove unbound labels and then incubated with trypsin (0.05%) at 37° C. Release of Gd (shown by □) and rhodamine (Rhx)(shown by ▪) was determined by T1 and optical density measurements. FIG. 3 compares Gd release and rhodamine release within the first 12 hours after incubation showing excellent correlation.

Non-covalent drug binding

In this set of experiments, hydrogel compositions were prepared as described in Example 2, and T1 label (Gd-DTPA), radioactive label (111-In-DTPA), and isosulfan blue (therapeutic drug model), were entrapped non-covalently in the hydrogel during synthesis. The gels were subsequently incubated in normal saline. Then T1 measurements, radioactivity measurements, and OD measurements of the supernatant were obtained at various time intervals. The graph in FIG. 4 summarizes the results.

These data indicate that there is an excellent correlation between the release of the model therapeutic drug (isosulfan blue) and the diagnostic labels (111-In or Gd). The release of either of the three compounds is virtually identical in hydrogels of different densities. For example, the best polynomial fit for two different gels are:

20% gel: f(x)=24.36x-17.87x2; r2=0.999

40% gel: f(x)=24.28x-17.11x2; r2=0.996

As shown in FIG. 5, the correlation between release of 111-In-DTPA and Gd-DTPA from the hydrogel is virtually identical. From knowing one concentration, the concentration of the other label can be mathematically estimated by imaging without additional physical measurements.

Drug release over time

The following experiment demonstrates the release of a non-covalently entrapped drug (modeled by isosulfan blue) from a 1 ml hydrogel sample. FIG. 6 shows the exponential release of the compound.

7. MR Imaging

The following experiments were performed to determine the degradation of hydrogels after surgical implantation into rats. Briefly, paramagnetic 0.5 ml hydrogels prepared as described in Example 2 were implanted into the left pararenal muscle groups (n=4), into the peritoneum (n=2), or subcutaneously (n=2) in rats (200 g CD, Charles River Breeders). The dissolution of these gels, which contained covalently bonded Gd-DTPA, could be observed over time by repeated MR imaging (1.5 T GE Medical Systems, SE 300/20). These studies show that peritoneally implanted samples degraded faster (4 days) than intramuscularly implanted samples (6 days). This is likely to be related to the higher concentration of peritoneal macrophages, capable of releasing proteases that enzymatically degrade the preferred hydrogels. FIG. 7 shows the dissolution of an implanted hydrogel button in a rat at 2, 5, and 10 days after implantation (from left to right).

8. Embolization

The following embolization experiment was designed to demonstrate that the preferred hydrogel compositions of this invention can be passed through interventional catheter systems, and that these hydrogels are suitable for intravascular embolization of tumors or organs.

A 2.5 kg New Zealand White rabbit was implanted with VX2 tumor cells in the flank. Several weeks after implantation the tumor had grown to a 5 cm solid mass infiltrating the retro-peritoneum. A right femoral artery cut-down was performed and a 3 Fr catheter was introduced and advanced into the aorta under fluoroscopic guidance (Fischer Imaging Systems). After injection of an iodinated contrast agent, feeding tumor vessels could be demonstrated to arise from the aorta. One of these vessels was cannulated and 0.2 ml of finely minced hydrogel beads (50-300 μm) were administered into that tumor vessel. Subsequent fluoroscopy demonstrated complete occlusion of the tumor vessel by the hydrogel.

In addition to the above experiment, the left renal artery was cannulated and 1 ml of hydrogel was administered. Complete occlusion of the renal artery and nonperfusion of the left kidney was demonstrated by subsequent MR angiography (1.5 T GE Imaging system, 3D-TOF sequence). FIG. 8 shows the results of this embolization procedure. The normally perfused right kidney (K) appears perfused (bright) after I.V. administration of a T1 agent whereas the left embolized kidney appears non-perfused (black).

9. Chemotherapeutic Drug Binding to Paramagnetic Hydrogel

A 40% solution of BSA with 10 mg BSA-Gd-DTPA in 0.1M carbonate buffer was prepared and the pH was adjusted to 8.5. 2 mg of doxorubicin (2 mg/ml; VHA plus) was added to this solution and the pH was adjusted with 0.05M HEPES buffer. 200 mg of cross-linking agent (see Example 1) was added and dissolved in 200 μl of DMSO. The sample was cross-linked at room temperature for 2 hours and then dialyzed in 0.9% NaCl for 24 hours. Binding of doxorubicin to the hydrogel matrix was greater than 95%.

10. Color coding

To easily recognize an entrapped or covalently bonded reporter group within a hydrogel, a chromophore, or mixtures of chromophores, may be added to the hydrogel during synthesis. A variety of chromophores are suitable including, e.g., indocyanine green, fluorescein, rhodamine, rose bengal, gentian violet, methylene blue, isosulfan blue, and other reactive colors (Sigma).

In the following example, a Gd-DTPA containing hydrogel was synthesized as described in Example 2. Briefly, a solution containing BSA and BSA-Gd-DTPA was reacted with 10 μl of DMSO to which had been added 5 μg of rhodamine X (Molecular Probes, Oregon). The solutions were reacted at room temperature for 15 minutes, cross-linked with activated PEG, and then washed to remove free rhodamine.

11. Lyophilization

Hydrogel prepared as described in Example 2 was subjected to lyophilization (Vitis Freezemobile) by first freezing the sample in liquid nitrogen. Lyophilized hydrogel samples were stored for two months and reconstituted with water to yield a hydrogel with properties similar in appearance, density and magnetic properties, to that of the non-lyophilized hydrogel.

12. Use of the Hydrogels as Contrast Agents Without Embolization

The hydrogel composition described in Example 2 was finely homogenized (Brinkman Polytron, Wheaton tissue homogenizer, Branson sonifier) to obtain an average particle size of below 100 nm. The size of the particles was controlled by passing the solution successively through 0.45 and 0.1 μm filters (Acrodisk). After concentration by centrifugation, 1 ml of the suspension was administered intravenously to a rat. Because the individual particles are too small to occlude capillaries, no embolization occurred and the animal survived the injection.

13. Coating of Interventional Devices with Paramagnetic Hydrogel

In the following experiment, an angiographic catheter was coated with a paramagnetic hydrogel for improved delineation by MR imaging. The surface of a 3 Fr angiographic catheter was cleaned with glass wool and ether. A section of the catheter was then submerged in a 20% BSA-(Gd-DTPA) solution (200 μl). The albumin adhered to the catheter non-specifically. The catheter was then dried at room temperature and subsequently immersed in 50 μg of DMSO solution containing the hydroxysuccinimide ester of PEG-bissuccinate of Example 1 to cross-link the albumin on the catheter. The catheter was then washed in saline and is ready for MR imaging.

14. Hydrogel Matrix for Cell Support

Living cells may be loaded into the hydrogel compositions and propagated to produce therapeutic agents. Such cells would have low or non-existent toxicity. For example, cells with the capacity to secrete therapeutic agents, e.g., insulin or other hormones, enzymes, or proteins, can be loaded into a hydrogel and implanted into a patient. If an appropriate label is also loaded into this hydrogel, an MR image will indicate cell density and activity, and/or the presence or concentration of the therapeutic agents, in the hydrogel.

To prepare such a hydrogel composition, the desired cells are dispersed, e.g., by vortexing, in a sterile solution of 10% serum, e.g., fetal calf, bovine, or human, in Dulbecco's modified Eagle medium at a pH of 7.9. At this stage, suitable therapeutic drugs and/or diagnostic labels as described above may be added. The number of cells loaded into the hydrogel is selected to achieve a specific dosage of the therapeutic agent secreted by the cells per day. For example, if the cells are secreting insulin, the standard dosage is about 10 to 80 I.U./day. This mixture is cross-linked by adding a cross-linking agent, e.g., the bis(N-hydroxy-succinimidyl)polyethylene glycol disuccinate described in Example 1, which is dissolved in DMSO. The cell loaded hydrogel is kept in tissue culture medium for a time sufficient to remove any DMSO or other contaminants, e.g., 12 to 24 hours, before implantation into a patient.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the preferred embodiments thereof, that the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US4113785 *29 oct. 197612 sept. 1978Basf Wyandotte CorporationPolyether polyols and method of preparing same
US4124705 *2 juin 19757 nov. 1978Pharmacia AktiebolagAgent for intravascular administration
US4126669 *9 févr. 197721 nov. 1978Pharmacia AktiebolagDiagnostic agent
US4684558 *30 juin 19864 août 1987Nepera Inc.Adhesive polyethylene oxide hydrogel sheet and its production
US4814098 *28 août 198721 mars 1989Bellex CorporationMagnetic material-physiologically active substance conjugate
US4865846 *3 juin 198812 sept. 1989Kaufman Herbert EDrug delivery system
US4976703 *15 févr. 198911 déc. 1990Siemens AktiengesellschaftMedical catheter for intravascular long-term infusion of medication with polysiloxane hydrogel coating
US4986980 *1 nov. 198522 janv. 1991Nycomed AsWater-soluble, carrier-bound paramagnetic metal containing diagnostic agents
US5008109 *11 oct. 198816 avr. 1991Vestar, Inc.Vesicle stabilization
US5032391 *9 août 199016 juil. 1991Gaf Chemicals CorporationHair styling gel composition
US5041292 *1 févr. 199020 août 1991Theratech, Inc.Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents
US5208324 *26 janv. 19894 mai 1993Nycomed Imaging AsParamagnetic compounds
EP0046136A2 *22 juil. 198117 févr. 1982Ciba-Geigy AgMembrane modified hydrogels, process for their manufacture and their use as active agent dispenser
EP0260098A2 *7 sept. 198716 mars 1988Bellex CorporationMagnetic material-physiologically active substance conjugate
WO1989011874A1 *2 juin 198914 déc. 1989Laurence David HallMagnetic resonance imaging
WO1991015753A1 *9 avr. 199117 oct. 1991Unger Evan CPolymers as contrast media for magnetic resonance imaging
Citations hors brevets
Référence
1 *Bischoff et al., Urol. Int., 32:323 335 (1977).
2Bischoff et al., Urol. Int., 32:323-335 (1977).
3 *Bligh et al., Magn. Reson. Med., 17:516 532 (1991).
4Bligh et al., Magn. Reson. Med., 17:516-532 (1991).
5 *Chazov et al., Thromb. Res., 12:809 816 (1978).
6Chazov et al., Thromb. Res., 12:809-816 (1978).
7 *Durand et al., Chapter 21 of Selected papers from Networks 88, 9th Polymer Network Group Meeting, Freiburg, West Germany, 26 30 Sep. 1988 pp. 283 301, W. Burchard and S. B. Ross Murphy editors.
8Durand et al., Chapter 21 of Selected papers from Networks '88, 9th Polymer Network Group Meeting, Freiburg, West Germany, 26-30 Sep. 1988 pp. 283-301, W. Burchard and S. B. Ross-Murphy editors.
9 *Fujimoto et al., Cancer, 56:2404 2410 (1985).
10Fujimoto et al., Cancer, 56:2404-2410 (1985).
11 *Gore et al., Magn. Reson. Med., 9:325 332 (1989).
12Gore et al., Magn. Reson. Med., 9:325-332 (1989).
13 *Hnatowich et al., J. Immunol. Meth., 65:147 157 (1983).
14Hnatowich et al., J. Immunol. Meth., 65:147-157 (1983).
15 *Jayakrishnan et al. J. Biomed. Mat. Res., 25:993 1004 (1990).
16Jayakrishnan et al. J. Biomed. Mat. Res., 25:993-1004 (1990).
17 *Kennedy et al., Am. Surg., 33:763 771 (1967).
18Kennedy et al., Am. Surg., 33:763-771 (1967).
19 *Krejcarek et al., Biochem. Biophys. Res. Comm., 77:581 586 (1977).
20Krejcarek et al., Biochem. Biophys. Res. Comm., 77:581-586 (1977).
21 *Larsen et al., J. Biomed. Mater. Res., 25:699 710 (1991).
22Larsen et al., J. Biomed. Mater. Res., 25:699-710 (1991).
23 *Link et al., Acta Radiol., 6:727 729 (1988).
24Link et al., Acta Radiol., 6:727-729 (1988).
25 *Mitsuhashi et al., Am. J. Path., 124:246 52 (1986).
26Mitsuhashi et al., Am. J. Path., 124:246-52 (1986).
27 *Rao et al., J. Neuroradiol., 18:61 69 (1991).
28Rao et al., J. Neuroradiol., 18:61-69 (1991).
29 *Shelub et al., J. Appl. Physiol., 56:810 15 (1984).
30Shelub et al., J. Appl. Physiol., 56:810-15 (1984).
31 *Szmigielski et al., Pol. Przeg. Rad., 47:387 90 (1983).
32Szmigielski et al., Pol. Przeg. Rad., 47:387-90 (1983).
33 *Torchilin et al., J. Biom. Mater. Res., 19:461 466 (1985).
34Torchilin et al., J. Biom. Mater. Res., 19:461-466 (1985).
35 *Torchilin et al., J. Biomed. Mater. Res., 11:223 234 (1977).
36Torchilin et al., J. Biomed. Mater. Res., 11:223-234 (1977).
37 *Verdon et al., Scan. Micro., 4:341 350 (1990).
38Verdon et al., Scan. Micro., 4:341-350 (1990).
39 *Weyne et al., Stroke, 18:128 37 (1987).
40Weyne et al., Stroke, 18:128-37 (1987).
41 *Winding, O., Neuroradiol., 21:123 126 (1981).
42Winding, O., Neuroradiol., 21:123-126 (1981).
43 *Wright et al., Radiology, 142:351 54 (1982).
44Wright et al., Radiology, 142:351-54 (1982).
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US5643575 *27 oct. 19931 juil. 1997Enzon, Inc.Non-antigenic branched polymer conjugates
US5851985 *16 août 199622 déc. 1998Tepic; SlobodanTreatment of tumors by arginine deprivation
US587450018 déc. 199623 févr. 1999Cohesion Technologies, Inc.Crosslinked polymer compositions and methods for their use
US5919455 *20 mars 19976 juil. 1999Enzon, Inc.Non-antigenic branched polymer conjugates
US5942209 *3 nov. 199724 août 1999Focal, Inc.Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel
US6015541 *3 nov. 199718 janv. 2000Micro Therapeutics, Inc.Radioactive embolizing compositions
US605164813 janv. 199918 avr. 2000Cohesion Technologies, Inc.Crosslinked polymer compositions and methods for their use
US6060040 *23 déc. 19979 mai 2000Bracco Research S.A.Cross-linked polymeric compositions for increasing the MRI contrast in visualising the digestive tract of patients
US6066325 *27 févr. 199823 mai 2000Fusion Medical Technologies, Inc.Fragmented polymeric compositions and methods for their use
US6107102 *7 août 199722 août 2000Regents Of The University Of CaliforniaTherapeutic microdevices and methods of making and using same
US6113629 *1 mai 19985 sept. 2000Micrus CorporationHydrogel for the therapeutic treatment of aneurysms
US6113906 *29 déc. 19985 sept. 2000Enzon, Inc.Water-soluble non-antigenic polymer linkable to biologically active material
US616613030 avr. 199926 déc. 2000Cohesion Technologies, Inc.Method of using crosslinked polymer compositions in tissue treatment applications
US61687773 nov. 19982 janv. 2001Micro Therapeutics, Inc.Methods for treating prostate tumors using radioactive compositions
US621431510 sept. 199910 avr. 2001Micro Therapeutics IncRadioactive embolizing compositions
US624196828 déc. 19995 juin 2001Bracco Research S.A.Compositions for increasing the MRI contrast in visualizing the digestive tract of patients
US626155717 déc. 199817 juil. 2001Slobodan TepicArginine decomposing enzyme therapeutic composition
US6310105 *15 févr. 200030 oct. 2001Wisconsin Alumni Research FoundationCarboxyl-modified superabsorbent protein hydrogel
US631272516 avr. 19996 nov. 2001Cohesion Technologies, Inc.Rapid gelling biocompatible polymer composition
US63232788 déc. 200027 nov. 2001Cohesion Technologies, Inc.Method of making crosslinked polymer matrices in tissue treatment applications
US63526822 oct. 19975 mars 2002Focal, Inc.Polymeric delivery of radionuclides and radiopharmaceuticals
US63567822 avr. 199912 mars 2002Vivant Medical, Inc.Subcutaneous cavity marking device and method
US63690373 oct. 20009 avr. 2002Cornell Research Foundation, Inc.Controlled release of doxorubicin
US63719042 juil. 199916 avr. 2002Vivant Medical, Inc.Subcutaneous cavity marking device and method
US63719756 nov. 199816 avr. 2002Neomend, Inc.Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
US638804720 mars 200014 mai 2002Cornell Research Foundation, Inc.Hydrogel-forming system with hydrophobic and hydrophilic components
US642614511 mai 200030 juil. 2002Scimed Life Systems, Inc.Radiopaque compositions for visualization of medical devices
US645809510 mars 20001 oct. 20023M Innovative Properties CompanyDispenser for an adhesive tissue sealant having a housing with multiple cavities
US64581471 avr. 19991 oct. 2002Neomend, Inc.Compositions, systems, and methods for arresting or controlling bleeding or fluid leakage in body tissue
US645888915 juin 20011 oct. 2002Cohesion Technologies, Inc.Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6472216 *24 juil. 200129 oct. 2002Ann-Shyn ChiangAqueous tissue clearing solution
US651453414 août 19984 févr. 2003Incept LlcMethods for forming regional tissue adherent barriers and drug delivery systems
US652514518 avr. 200125 févr. 2003Clemson UniversityPolylactide/dextran graft co-polymers for biomaterial and tissue engineering applications
US653459117 août 200118 mars 2003Cohesion Technologies, Inc.Cross-linked polymer compositions and methods for their use
US656231720 févr. 200113 mai 2003Micro Therapeutics, Inc.Radioactive embolizing compositions
US65664063 déc. 199920 mai 2003Incept, LlcBiocompatible crosslinked polymers
US65665067 avr. 200020 mai 2003Enzon, Inc.Non-antigenic branched polymer conjugates
US65691139 août 200227 mai 20033M Innovative Properties CompanyDispenser for an adhesive tissue sealant
US656968813 août 199827 mai 2003Technion Research & Development Foundation Ltd.Intravascular apparatus method
US657622617 nov. 200010 juin 2003Gary R. JernbergLocal delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US658321913 mars 200224 juin 2003Cornell Research Foundation, Inc.Hydrogel-forming system with hydrophobic and hydrophilic components
US66242455 nov. 200123 sept. 2003Cohesion Technologies, Inc.Rapid-gelling biocompatible polymer composition and associated methods of preparation and use
US664885227 mars 200318 nov. 20033M Innovative Peroperties CompanyDispenser for an adhesive tissue sealant
US665288313 mars 200125 nov. 2003Biocure, Inc.Tissue bulking and coating compositions
US666024723 juin 20009 déc. 2003Battelle Memorial InstituteMultiple stimulus reversible hydrogels
US667697113 mars 200113 janv. 2004Biocure, Inc.Embolic compositions
US670966821 févr. 200323 mars 2004Cornell Research Foundation, Inc.Hydrogel-forming system with hydrophobic and hydrophilic components
US671644513 mai 20026 avr. 2004Cornell Research Foundation, Inc.Hydrogel entrapping therapeutic agent and stent with coating comprising this
US67268986 juin 200327 avr. 2004Gary R. JernbergLocal delivery of agents for disruption and inhibition of bacterial biofilm for treatment of periodontal disease
US674324813 avr. 20001 juin 2004Neomend, Inc.Pretreatment method for enhancing tissue adhesion
US681801814 août 199816 nov. 2004Incept LlcIn situ polymerizable hydrogels
US68307569 févr. 200114 déc. 2004Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US683340830 sept. 200221 déc. 2004Cohesion Technologies, Inc.Methods for tissue repair using adhesive materials
US684692318 sept. 200125 janv. 2005Hercules, Inc.Oxime-linked polysaccharides and methods of preparing the same
US68879745 févr. 20023 mai 2005Incept LlcCrosslinking agents and methods of use
US68998897 mars 200031 mai 2005Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US690570023 janv. 200414 juin 2005Cornell Research Foundation, Inc.Hydrogel entrapping therapeutic agent and stent with coating comprising this
US691685712 déc. 200312 juil. 2005Cornell Research Foundation, Inc.Hydrogel-forming system with hydrophobic and hydrophilic components
US69491149 févr. 200127 sept. 2005Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US697946411 déc. 199827 déc. 2005Battelle Memorial InstituteReversible geling co-polymer and method of making
US699468628 févr. 20017 févr. 2006Neomend, Inc.Systems for applying cross-linked mechanical barriers
US70086358 sept. 20007 mars 2006Genzyme CorporationHydrogels for orthopedic repair
US70090349 nov. 20017 mars 2006Incept, LlcBiocompatible crosslinked polymers
US70259908 oct. 200211 avr. 2006Incept LlcMethods for forming regional tissue adherent barriers and drug delivery systems
US70335713 nov. 200325 avr. 2006Battelle Memorial InstituteMultiple stimulus reversible hydrogels
US70564666 août 20026 juin 2006Scimed Life Systems, Inc.Method of manufacture medical devices employing microwave energy
US705701911 févr. 20036 juin 2006Incept LlcCrosslinked albumin hydrogels
US707080913 mars 20014 juil. 2006Biocure, Inc.Hydrogel biomedical articles
US713813219 janv. 200521 nov. 2006Cornell Research Foundation, Inc.Hydrogel entrapping therapeutic agent and stent with coating comprising this
US716365517 janv. 200316 janv. 2007Scimed Life Systems, Inc.Method and apparatus for extruding polymers employing microwave energy
US718678911 juin 20036 mars 2007Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings
US721165113 nov. 20021 mai 2007Incept LlcProteinaceous gels having visualization agents and methods of use thereof
US7229417 *15 oct. 200412 juin 2007Ethicon Endo-Surgery, Inc.Methods for marking a biopsy site
US722947110 sept. 200412 juin 2007Advanced Cardiovascular Systems, Inc.Compositions containing fast-leaching plasticizers for improved performance of medical devices
US72473142 déc. 200424 juil. 2007Neomend, IncBiocompatible material composition adaptable to diverse therapeutic indications
US72790018 mai 20029 oct. 2007Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US728530425 juin 200323 oct. 2007Advanced Cardiovascular Systems, Inc.Fluid treatment of a polymeric coating on an implantable medical device
US729116618 mai 20056 nov. 2007Advanced Cardiovascular Systems, Inc.Polymeric stent patterns
US72977582 août 200520 nov. 2007Advanced Cardiovascular Systems, Inc.Method for extending shelf-life of constructs of semi-crystallizable polymers
US730100120 déc. 200627 nov. 2007Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial polyester polymers for stent coatings
US7306622 *23 juin 200411 déc. 2007Cordis Neurosvascular, Inc.Stent embolization device
US731229920 déc. 200625 déc. 2007Advanced Cardiovascular Systems, Inc.Bioabsorbabl, biobeneficial polyester polymers for stent coatings
US731893322 oct. 200415 janv. 2008Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US732936618 juin 200412 févr. 2008Advanced Cardiovascular Systems Inc.Method of polishing implantable medical devices to lower thrombogenecity and increase mechanical stability
US73325662 déc. 200519 févr. 2008Incept LlcBiocompatible crosslinked polymers with visualization agents
US734785013 déc. 200225 mars 2008Incept LlcAdhesion barriers applicable by minimally invasive surgery and methods of use thereof
US7371225 *24 sept. 200313 mai 2008The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesMethod for convection enhanced delivery of therapeutic agents
US738104812 avr. 20053 juin 2008Advanced Cardiovascular Systems, Inc.Stents with profiles for gripping a balloon catheter and molds for fabricating stents
US739033310 janv. 200324 juin 2008Advanced Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US745879827 nov. 20062 déc. 2008Boston Scientific Scimed, Inc.Apparatus for extruding polymers employing microwave energy
US747028310 janv. 200330 déc. 2008Advanced Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US747624516 août 200513 janv. 2009Advanced Cardiovascular Systems, Inc.Polymeric stent patterns
US753112228 mars 200312 mai 2009Boston Scientific Scimed, Inc.Polymer welding using ferromagnetic particles
US7560275 *3 mars 200314 juil. 2009Vbi Technologies, L.L.C.Compositions and methods for generating skin
US7572288 *20 juil. 200111 août 2009Microvention, Inc.Aneurysm treatment device and method of use
US759241813 févr. 200822 sept. 2009Incept LlcBiocompatible crosslinked polymers with visualization agents
US760523220 mars 200720 oct. 2009Incept LlcHydrogels for protein concentration
US76487139 juil. 200319 janv. 2010Incept LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US765888029 juil. 20059 févr. 2010Advanced Cardiovascular Systems, Inc.Polymeric stent polishing method and apparatus
US766232627 avr. 200716 févr. 2010Advanced Cardiovascular Systems, Inc.Compositions containing fast-leaching plasticizers for improved performance of medical devices
US7666225 *29 juin 200523 févr. 2010Hassan ChaoukSpinal disc nucleus pulposus implant
US76685827 oct. 200423 févr. 2010Ethicon Endo-Surgery, Inc.Biopsy site marker
US769989028 janv. 200420 avr. 2010Advanced Cardiovascular Systems, Inc.Medicated porous metal prosthesis and a method of making the same
US770854810 avr. 20084 mai 2010Advanced Cardiovascular Systems, Inc.Molds for fabricating stents with profiles for gripping a balloon catheter
US77275472 avr. 20041 juin 2010Tissuemed LimitedTissue-adhesive formulations
US773189015 juin 20068 juin 2010Advanced Cardiovascular Systems, Inc.Methods of fabricating stents with enhanced fracture toughness
US774079130 juin 200622 juin 2010Advanced Cardiovascular Systems, Inc.Method of fabricating a stent with features by blow molding
US775754313 juil. 200620 juil. 2010Advanced Cardiovascular Systems, Inc.Radio frequency identification monitoring of stents
US775888124 mars 200520 juil. 2010Advanced Cardiovascular Systems, Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US776196825 mai 200627 juil. 2010Advanced Cardiovascular Systems, Inc.Method of crimping a polymeric stent
US777606321 déc. 200717 août 2010Incept LlcIn situ materials formation
US778098019 avr. 200624 août 2010Incept, LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US77901419 août 20047 sept. 2010Pathak Holdings, LlcRadio-opaque compounds, compositions containing same and methods of their synthesis and use
US779449517 juil. 200614 sept. 2010Advanced Cardiovascular Systems, Inc.Controlled degradation of stents
US779477629 juin 200614 sept. 2010Abbott Cardiovascular Systems Inc.Modification of polymer stents with radiation
US7799767 *21 févr. 200321 sept. 2010Pioneer Surgical Orthobiologics, Inc.Cross-linked bioactive hydrogel matrices
US78232639 juil. 20072 nov. 2010Abbott Cardiovascular Systems Inc.Method of removing stent islands from a stent
US782900830 mai 20079 nov. 2010Abbott Cardiovascular Systems Inc.Fabricating a stent from a blow molded tube
US783869914 mars 200323 nov. 2010Biosphere MedicalEmbolization using degradable crosslinked hydrogels
US784237723 sept. 200830 nov. 2010Boston Scientific Scimed, Inc.Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US784273729 sept. 200630 nov. 2010Abbott Cardiovascular Systems Inc.Polymer blend-bioceramic composite implantable medical devices
US78625384 févr. 20084 janv. 2011Incept LlcSurgical delivery system for medical sealant
US786754719 déc. 200511 janv. 2011Advanced Cardiovascular Systems, Inc.Selectively coating luminal surfaces of stents
US787163721 sept. 200718 janv. 2011Baxter International Inc.Dry hemostatic compositions and methods for their preparation
US787206830 mai 200618 janv. 2011Incept LlcMaterials formable in situ within a medical device
US787523318 juil. 200525 janv. 2011Advanced Cardiovascular Systems, Inc.Method of fabricating a biaxially oriented implantable medical device
US787528316 juin 200525 janv. 2011Advanced Cardiovascular Systems, Inc.Biodegradable polymers for use with implantable medical devices
US788369331 janv. 20068 févr. 2011Angiodevice International GmbhCompositions and systems for forming crosslinked biomaterials and methods of preparation of use
US788369427 janv. 20048 févr. 2011Angiodevice International GmbhMethod for preventing the formation of adhesions following surgery or injury
US788641918 juil. 200615 févr. 2011Advanced Cardiovascular Systems, Inc.Stent crimping apparatus and method
US789687929 juil. 20051 mars 2011Vertos Medical, Inc.Spinal ligament modification
US790145227 juin 20078 mars 2011Abbott Cardiovascular Systems Inc.Method to fabricate a stent having selected morphology to reduce restenosis
US79017702 mars 20048 mars 2011Boston Scientific Scimed, Inc.Embolic compositions
US791454113 avr. 200729 mars 2011Incept, LlcIn situ materials formation
US791911224 août 20055 avr. 2011Pathak Holdings, LlcImplantable tissue compositions and method
US792302213 sept. 200612 avr. 2011Advanced Cardiovascular Systems, Inc.Degradable polymeric implantable medical devices with continuous phase and discrete phase
US793957830 août 200710 mai 20113M Innovative Properties CompanyPolymeric fibers and methods of making
US79428309 mai 200617 mai 2011Vertos Medical, Inc.Ipsilateral approach to minimally invasive ligament decompression procedure
US7943569 *16 nov. 200717 mai 2011The Board Of Trustees Of The University Of IllinoisComposition and method for providing localized delivery of a therapeutic agent
US79511856 janv. 200631 mai 2011Advanced Cardiovascular Systems, Inc.Delivery of a stent at an elevated temperature
US795119422 mai 200731 mai 2011Abbott Cardiovascular Sysetms Inc.Bioabsorbable stent with radiopaque coating
US795140223 sept. 200831 mai 2011Boston Scientific Scimed, Inc.Drug delivery particle
US795538129 juin 20077 juin 2011Advanced Cardiovascular Systems, Inc.Polymer-bioceramic composite implantable medical device with different types of bioceramic particles
US79598571 juin 200714 juin 2011Abbott Cardiovascular Systems Inc.Radiation sterilization of medical devices
US795994030 mai 200614 juin 2011Advanced Cardiovascular Systems, Inc.Polymer-bioceramic composite implantable medical devices
US79641235 janv. 201021 juin 2011Boston Scientific Scimed, Inc.Embolization
US796421031 mars 200621 juin 2011Abbott Cardiovascular Systems Inc.Degradable polymeric implantable medical devices with a continuous phase and discrete phase
US796439417 juil. 200921 juin 2011Vbi Technologies, L.L.C.Spore-like cells and uses thereof
US79679983 janv. 200828 juin 2011Advanced Cardiocasvular Systems, Inc.Method of polishing implantable medical devices to lower thrombogenecity and increase mechanical stability
US797133330 mai 20065 juil. 2011Advanced Cardiovascular Systems, Inc.Manufacturing process for polymetric stents
US797682327 août 200412 juil. 2011Boston Scientific Scimed, Inc.Ferromagnetic particles and methods
US798901831 mars 20062 août 2011Advanced Cardiovascular Systems, Inc.Fluid treatment of a polymeric coating on an implantable medical device
US799840413 juil. 200616 août 2011Advanced Cardiovascular Systems, Inc.Reduced temperature sterilization of stents
US80031564 mai 200623 août 2011Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US800370529 mai 200823 août 2011Incept LlcBiocompatible hydrogels made with small molecule precursors
US80075291 août 200830 août 2011Advanced Cardiovascular Systems, Inc.Medicated porous metal prosthesis
US8012454 *29 août 20036 sept. 2011Boston Scientific Scimed, Inc.Embolization
US801687927 juin 200713 sept. 2011Abbott Cardiovascular Systems Inc.Drug delivery after biodegradation of the stent scaffolding
US801723723 juin 200613 sept. 2011Abbott Cardiovascular Systems, Inc.Nanoshells on polymers
US803428715 mai 200711 oct. 2011Abbott Cardiovascular Systems Inc.Radiation sterilization of medical devices
US803436721 déc. 200711 oct. 2011Neomend, Inc.Tissue adhering compositions
US804355330 sept. 200425 oct. 2011Advanced Cardiovascular Systems, Inc.Controlled deformation of a polymer tube with a restraining surface in fabricating a medical article
US804413716 déc. 201025 oct. 2011Incept LlcMaterials formable in situ within a medical device
US804840726 avr. 20041 nov. 2011Brent VernonIn situ gelling self-reactive materials for embolization
US804844125 juin 20071 nov. 2011Abbott Cardiovascular Systems, Inc.Nanobead releasing medical devices
US804844815 juin 20061 nov. 2011Abbott Cardiovascular Systems Inc.Nanoshells for drug delivery
US805342318 mai 20108 nov. 2011Encelle, Inc.Method of preparing cross-linked bioactive hydrogel matrices
US80670281 juil. 200829 nov. 2011Confluent Surgical Inc.Drug delivery device
US806703128 avr. 200529 nov. 2011Angiodevice International GmbhCompositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US8067073 *25 mars 200429 nov. 2011Boston Scientific Scimed, Inc.Thermoplastic medical device
US809282019 mai 200910 janv. 2012Baxter International Inc.Dry hemostatic compositions and methods for their preparation
US809283727 avr. 200710 janv. 2012Biomet Manufacturing CorpFibrin based glue with functionalized hydrophilic polymer protein binding agent
US809984913 déc. 200624 janv. 2012Abbott Cardiovascular Systems Inc.Optimizing fracture toughness of polymeric stent
US81056228 août 200731 janv. 2012Incept LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US81099942 janv. 20087 févr. 2012Abbott Cardiovascular Systems, Inc.Biodegradable drug delivery material for stent
US811885627 juil. 201021 févr. 2012Endologix, Inc.Stent graft
US812868819 juin 20076 mars 2012Abbott Cardiovascular Systems Inc.Carbon coating on an implantable device
US81333362 févr. 200713 mars 2012Tissuemed LimitedTissue-adhesive materials
US813350429 juil. 200513 mars 2012Tissuemed LimitedTissue-adhesive materials
US81428709 déc. 200827 mars 2012Personics Holdings Inc.Energy responsive conformal device
US8163326 *12 déc. 200624 avr. 2012Boston Scientific Scimed, Inc.Implantable or insertable medical devices visible under magnetic resonance imaging
US817289728 juin 20048 mai 2012Advanced Cardiovascular Systems, Inc.Polymer and metal composite implantable medical devices
US817306230 sept. 20048 mai 2012Advanced Cardiovascular Systems, Inc.Controlled deformation of a polymer tube in fabricating a medical article
US819780228 déc. 201012 juin 2012Angiodevice International GmbhMethod for treating or inhibiting the formation of adhesions following surgery or injury
US819787916 janv. 200712 juin 2012Advanced Cardiovascular Systems, Inc.Method for selectively coating surfaces of a stent
US82025285 juin 200719 juin 2012Abbott Cardiovascular Systems Inc.Implantable medical devices with elastomeric block copolymer coatings
US82027246 oct. 201019 juin 2012Gamida Cell Ltd.Methods of controlling proliferation and differentiation of stem and progenitor cells
US822145213 févr. 200817 juil. 2012Neomend, Inc.Systems and methods for sealing a vascular puncture
US822173523 avr. 200917 juil. 2012Biocure, Inc.Embolic compositions
US82218605 mai 200817 juil. 2012Personics Holdings Inc.Earguard sealing system I: multi-chamber systems
US82218615 mai 200817 juil. 2012Personics Holdings Inc.Earguard sealing system II: single-chamber systems
US824155429 juin 200414 août 2012Advanced Cardiovascular Systems, Inc.Method of forming a stent pattern on a tube
US8241609 *20 août 200814 août 2012E I Du Pont De Nemours And CompanyMethod for embolization using liquid embolic materials
US82627239 avr. 200711 sept. 2012Abbott Cardiovascular Systems Inc.Implantable medical devices fabricated from polymer blends with star-block copolymers
US8268345 *3 déc. 200818 sept. 2012Transdermal Innovations Inc.Multipurpose hydrogel compositions and products
US827332426 juil. 201125 sept. 2012Boston Scientific Scimed, Inc.Embolization
US827332721 juil. 201025 sept. 2012Pathak Holdings, LlcRadio-opaque compounds, compositions containing same and methods of their synthesis and use
US8277391 *7 août 20022 oct. 2012Devicor Medical Products, Inc.Methods and devices for defining and marking tissue
US828295927 nov. 20079 oct. 2012Actamax Surgical Materials, LlcBranched end reactants and polymeric hydrogel tissue adhesives therefrom
US82928224 mai 200423 oct. 2012Devicor Medical Products, Inc.Biopsy localization method and device
US82932605 juin 200723 oct. 2012Abbott Cardiovascular Systems Inc.Elastomeric copolymer coatings containing poly (tetramethyl carbonate) for implantable medical devices
US829336715 juil. 201123 oct. 2012Advanced Cardiovascular Systems, Inc.Nanoshells on polymers
US83039811 juil. 20116 nov. 2012Baxter International Inc.Fragmented polymeric compositions and methods for their use
US830660230 sept. 20056 nov. 2012Devicor Medical Products, Inc.Biopsy cavity marking device
US832099313 mars 200127 nov. 2012Devicor Medical Products, Inc.Subcutaneous cavity marking device
US83209946 oct. 200427 nov. 2012Devicor Medical Products, Inc.Biopsy cavity marking device and method
US833300019 juin 200618 déc. 2012Advanced Cardiovascular Systems, Inc.Methods for improving stent retention on a balloon catheter
US834353022 déc. 20061 janv. 2013Abbott Cardiovascular Systems Inc.Polymer-and polymer blend-bioceramic composite implantable medical devices
US835737824 mai 201122 janv. 2013Baxter International Inc.Fragmented polymeric compositions and methods for their use
US837746622 oct. 200419 févr. 2013Angiotech Pharmaceuticals (Us), Inc.Adhesive tissue repair patch
US838314121 juil. 200826 févr. 2013Baxter International Inc.Dry hemostatic compositions and methods for their preparation
US838314417 déc. 200926 févr. 2013Neomend, Inc.Tissue adhering compositions
US838316115 déc. 201026 févr. 2013Incept, LlcRadioopaque covalently crosslinked hydrogel particle implants
US84096053 juin 20092 avr. 2013Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US840960612 févr. 20102 avr. 2013Incept, LlcDrug delivery through hydrogel plugs
US840970323 juil. 20102 avr. 2013E I Du Pont De Nemours And CompanyTemperature switchable adhesive assemblies with temperature non-switchable tack
US84146421 déc. 20089 avr. 2013Advanced Cardiovascular Systems, Inc.Biodegradable stent of a polyorthoester polymer or a polyanhydride polymer
US842559111 juin 200723 avr. 2013Abbott Cardiovascular Systems Inc.Methods of forming polymer-bioceramic composite medical devices with bioceramic particles
US842649214 nov. 200823 avr. 2013Actamax Surgical Materials, LlcOxidized cationic polysaccharide-based polymer tissue adhesive for medical use
US84311146 oct. 200530 avr. 2013Actamax Surgical Materials, LlcPolysaccharide-based polymer tissue adhesive for medical use
US843555013 août 20087 mai 2013Abbot Cardiovascular Systems Inc.Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US84497148 déc. 200628 mai 2013Covidien LpBiocompatible surgical compositions
US846070824 oct. 201111 juin 2013Angiodevice International GmbhCompositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US846578918 juil. 201118 juin 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US846632731 août 200918 juin 2013Actamax Surgical Materials, LlcAldehyde-functionalized polyethers and method of making same
US847001414 août 200725 juin 2013Advanced Cardiovascular Systems, Inc.Stent-catheter assembly with a releasable connection for stent retention
US847035522 sept. 201025 juin 2013Covidien LpMesh implant
US848107324 oct. 20119 juil. 2013Angiodevice International GmbhCompositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US84861359 avr. 200716 juil. 2013Abbott Cardiovascular Systems Inc.Implantable medical devices fabricated from branched polymers
US851272931 oct. 201220 août 2013Baxter International Inc.Fragmented polymeric compositions and methods for their use
US85133227 juin 200720 août 20133M Innovative Properties CompanyPolymeric beads and methods of making polymeric beads
US851844021 déc. 201027 août 2013Confluent Surgical, Inc.Biodegradable osmotic pump implant for drug delivery
US853537218 juin 200717 sept. 2013Abbott Cardiovascular Systems Inc.Bioabsorbable stent with prohealing layer
US853570516 nov. 200717 sept. 2013Incept, LlcBiocompatible polymers and hydrogels and methods of use
US85511366 juil. 20098 oct. 2013Actamax Surgical Materials, LlcHigh swell, long-lived hydrogel sealant
US855177511 nov. 20108 oct. 2013Vbi Technologies, L.L.C.Subpopulations of spore-like cells and uses thereof
US85575359 sept. 200915 oct. 2013Incept LlcMethods for preparation of platelet rich plasma
US8562667 *28 juil. 200922 oct. 2013Microvention, Inc.Aneurysm treatment device and method of use
US856302726 févr. 201322 oct. 2013Incept, LlcDrug delivery through hydrogel plugs
US856846928 juin 200429 oct. 2013Advanced Cardiovascular Systems, Inc.Stent locking element and a method of securing a stent on a delivery system
US858095021 déc. 201012 nov. 2013Actamax Surgical Materials, LlcAldehyde-functionalized polysaccharides
US85809511 juil. 201012 nov. 2013Actamax Surgical Materials, LlcAldehyde-functionalized polysaccharides
US858575413 janv. 201219 nov. 2013Abbott Cardiovascular Systems Inc.Stent formed of a Biodegradable material
US859192924 mai 201126 nov. 2013Covidien LpHydrogel implants with varying degrees of crosslinking
US859195024 mai 201126 nov. 2013Covidien LpHydrogel implants with varying degrees of crosslinking
US859203620 sept. 201226 nov. 2013Abbott Cardiovascular Systems Inc.Nanoshells on polymers
US859621518 juil. 20113 déc. 2013Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US86004815 sept. 20123 déc. 2013Devicor Medical Products, Inc.Subcutaneous cavity marking device
US860351118 janv. 201310 déc. 2013Baxter International, Inc.Fragmented polymeric compositions and methods for their use
US860353014 juin 200610 déc. 2013Abbott Cardiovascular Systems Inc.Nanoshell therapy
US86087628 août 200817 déc. 2013Vertos Medical, Inc.Translaminar approach to minimally invasive ligament decompression procedure
US86172064 oct. 201031 déc. 2013Covidien LpWound closure device
US861758425 mai 201031 déc. 2013Angiodevice International GmbhAdhesive tissue repair patch and collagen sheets
US862339329 avr. 20037 janv. 2014Gel-Del Technologies, Inc.Biomatrix structural containment and fixation systems and methods of use thereof
US863711018 juil. 201128 janv. 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US865250421 sept. 200618 févr. 2014Medivas, LlcSolid polymer delivery compositions and methods for use thereof
US86642024 oct. 20114 mars 2014Pioneer Surgical Technology, Inc.Cross-linked bioactive hydrogel matrices
US867953624 août 200625 mars 2014Actamax Surgical Materials, LlcAldol-crosslinked polymeric hydrogel adhesives
US867953724 août 200625 mars 2014Actamaz Surgical Materials, LLCMethods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
US869667131 juil. 200615 avr. 2014Vertos Medical Inc.Percutaneous tissue excision devices
US86969758 déc. 200815 avr. 20143M Innovative Properties CompanyMethods of making shaped polymeric materials
US869711112 mai 201015 avr. 2014Covidien LpOsteochondral implant comprising osseous phase and chondral phase
US8697137 *23 mars 200115 avr. 2014Biosphere Medical, Inc.Methods of using microspheres for active embolization
US870312230 mai 200722 avr. 2014Baxter International Inc.Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US87031707 avr. 201122 avr. 2014Baxter International Inc.Hemostatic sponge
US87156368 mars 20136 mai 2014Actamax Surgical Materials, LlcPolysaccharide-based polymer tissue adhesive for medical use
US871831310 nov. 20086 mai 2014Personics Holdings, LLC.Electroactive polymer systems
US873447720 sept. 201327 mai 2014Vertos Medical, Inc.Translaminar approach to minimally invasive ligament decompression procedure
US873482424 mai 201127 mai 2014Covidien LLPHydrogel implants with varying degrees of crosslinking
US873493031 août 201127 mai 2014Covidien LpHydrogel implants with varying degrees of crosslinking
US874137918 juil. 20113 juin 2014Advanced Cardiovascular Systems, Inc.Rotatable support elements for stents
US874787828 avr. 200610 juin 2014Advanced Cardiovascular Systems, Inc.Method of fabricating an implantable medical device by controlling crystalline structure
US874787931 mai 200610 juin 2014Advanced Cardiovascular Systems, Inc.Method of fabricating an implantable medical device to reduce chance of late inflammatory response
US87522679 août 201317 juin 2014Abbott Cardiovascular Systems Inc.Method of making stents with radiopaque markers
US87522689 août 201317 juin 2014Abbott Cardiovascular Systems Inc.Method of making stents with radiopaque markers
US875456431 août 201117 juin 2014Covidien LpHydrogel implants with varying degrees of crosslinking
US877125816 déc. 20108 juil. 2014Baxter International Inc.Hemostatic sponge
US87717388 mars 20138 juil. 2014Actamax Surgical Materials, LlcPolysaccharide-based polymer tissue adhesive for medical use
US877825630 sept. 200415 juil. 2014Advanced Cardiovascular Systems, Inc.Deformation of a polymer tube in the fabrication of a medical article
US877832630 juin 201015 juil. 2014Actamax Surgical Materials, LlcHydrogel tissue adhesive for medical use
US87904882 janv. 201329 juil. 2014Covidien LpBiocompatible surgical compositions
US87906325 oct. 200529 juil. 2014Actamax Surgical Materials, LlcPolymer-based tissue-adhesive form medical use
US879069829 oct. 200829 juil. 2014Baxter International Inc.Use of a regenerative biofunctional collagen biomatrix for treating visceral or parietal defects
US879570918 août 20065 août 2014Incept LlcSuperabsorbent, freeze dried hydrogels for medical applications
US87957275 nov. 20105 août 2014Spotlight Technology Partners LlcFragmented hydrogels
US879624212 mars 20135 août 2014Actamax Surgical Materials, LlcHydrogel tissue adhesive for medical use
US880834223 avr. 201319 août 2014Abbott Cardiovascular Systems Inc.Nanoshell therapy
US882156416 févr. 20122 sept. 2014Endologix, Inc.Stent graft
US882184926 mars 20102 sept. 2014Genzyme CorporationInternal clamp for surgical procedures
US882818130 avr. 20109 sept. 2014E I Du Pont De Nemours And CompanyTemperature switchable adhesives comprising a crystallizable oil
US88348641 déc. 200516 sept. 2014Baxter International Inc.Methods for repairing and regenerating human dura mater
US884607029 juil. 200830 sept. 2014Advanced Cardiovascular Systems, Inc.Biologically degradable compositions for medical applications
US884609514 nov. 200830 sept. 2014Actamax Surgical Materials, LlcDextran-based polymer tissue adhesive for medical use
US884659512 juin 200930 sept. 20143M Innovative Properties CompanyMethod of making a cleaning solution from hydrogel cleaning concentrate and packaged cleaning concentrate
US885264625 janv. 20137 oct. 2014Incept, LlcParticulate implants and biodegradable fiducial markers
US885859228 oct. 201014 oct. 2014Covidien LpWound plugs
US885970519 nov. 201214 oct. 2014Actamax Surgical Materials LlcHydrogel tissue adhesive having decreased gelation time and decreased degradation time
US886220327 mars 200314 oct. 2014Boston Scientific Scimed Inc.Medical device with temperature modulator for use in magnetic resonance imaging
US88712675 févr. 201028 oct. 2014Gel-Del Technologies, Inc.Protein matrix materials, devices and methods of making and using thereof
US888277220 sept. 201311 nov. 2014Vertos Medical, Inc.Percutaneous tissue excision devices and methods
US888318524 mai 201111 nov. 2014Covidien LpHydrogel implants with varying degrees of crosslinking
US88946535 sept. 201325 nov. 2014Vertos Medical, Inc.Percutaneous tissue excision devices and methods
US890109222 déc. 20112 déc. 2014Surmodics, Inc.Functionalized polysaccharides for active agent delivery
US892517717 juil. 20126 janv. 2015Abbott Cardiovascular Systems Inc.Methods for improving stent retention on a balloon catheter
US893261811 juil. 201313 janv. 2015Confluent Surgical, Inc.Biodegradable osmotic pump implant for drug delivery
US89326221 juin 200913 janv. 2015Actamax Surgical Materials, LlcTissue coating for preventing undesired tissue-to-tissue adhesions
US89368117 mai 200920 janv. 2015Surmodics, Inc.Device coated with glycogen particles comprising nucleic acid complexes
US894031720 déc. 201227 janv. 2015Pioneer Surgical TechnologyContinuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith
US89403351 juin 201127 janv. 2015Baxter International Inc.Process for making dry and stable hemostatic compositions
US89519899 avr. 201010 févr. 2015Actamax Surgical Materials, LlcHydrogel tissue adhesive having reduced degradation time
US895705011 mars 201317 févr. 2015Pioneer Surgical Technology, Inc.Bone implant materials comprising cross-linked bioactive hydrogel matrices
US896150117 sept. 201024 févr. 2015Incept, LlcMethod for applying flowable hydrogels to a cornea
US896194714 avr. 200824 févr. 2015Kuros Biosurgery AgPolymeric tissue sealant
US89620251 août 200724 févr. 2015Baxter International Inc.Rapidly acting dry sealant and methods for use and manufacture
US896878324 mai 20113 mars 2015Covidien LpHydrogel implants with varying degrees of crosslinking
US896878523 sept. 20103 mars 2015Covidien LpSurgical compositions
US898660928 oct. 201024 mars 2015Ascendis Pharma A/SSterilization of biodegradable hydrogels
US900560930 mars 201014 avr. 2015Ethicon, Inc.Hemostatic compositions containing sterile thrombin
US901061025 août 201421 avr. 2015Covidien LpButtress retention system for linear endostaplers
US902309425 juin 20085 mai 2015Microvention, Inc.Self-expanding prosthesis
US90382608 mai 201426 mai 2015Abbott Cardiovascular Systems Inc.Stent with radiopaque markers
US903978318 mai 200926 mai 2015Baxter International, Inc.Method for the improvement of mesh implant biocompatibility
US904002214 févr. 201426 mai 2015Biosphere Medical, S.A.Compositions and methods using microspheres and non-ionic contrast agents
US904452931 août 20092 juin 2015Actamax Surgical Materials, LlcHydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
US907282026 juin 20067 juil. 2015Advanced Cardiovascular Systems, Inc.Polymer composite stent with polymer particles
US908460226 janv. 201121 juil. 2015Covidien LpButtress film with hemostatic action for surgical stapling apparatus
US90847281 juin 201121 juil. 2015Baxter International Inc.Process for making dry and stable hemostatic compositions
US910283015 mars 201311 août 2015Medivas, LlcBis-(α-amino)-diol-diester-containing poly (ester amide) and poly (ester urethane) compositions and methods of use
US910766516 sept. 201418 août 2015Covidien LpSurgical instrument buttress attachment
US910766715 déc. 201418 août 2015Covidien LpSurgical stapling apparatus including releasable buttress
US911417228 févr. 201325 août 2015Baxter International Inc.Rapidly acting dry sealant and methods for use and manufacture
US91258079 juil. 20078 sept. 2015Incept LlcAdhesive hydrogels for ophthalmic drug delivery
US913220727 oct. 200915 sept. 2015Spine Wave, Inc.Radiopaque injectable nucleus hydrogel compositions
US913327616 sept. 201115 sept. 2015Sanofi-Aventis Deutschland GmbhProdrugs comprising an exendin linker conjugate
US913846230 juil. 201022 sept. 2015Sanofi-Aventis Deutschland GmbhProdrugs comprising an insulin linker conjugate
US91446117 oct. 201429 sept. 2015Covidien LpHydrogel implants with varying degrees of crosslinking
US914554512 sept. 201329 sept. 2015Vbi Technologies, LlcSubpopulations of spore-like cells and uses thereof
US916200616 juin 201020 oct. 2015Baxter International Inc.Hemostatic sponge
US917373321 août 20063 nov. 2015Abbott Cardiovascular Systems Inc.Tracheobronchial implantable medical device and methods of use
US918022216 janv. 201510 nov. 2015Kuros Biosurgery AgPolymeric tissue sealant
US918614423 févr. 201517 nov. 2015Covidien LpButtress support design for EEA anvil
US91986608 avr. 20151 déc. 2015Covidien LpButtress retention system for linear endostaplers
US919866329 juil. 20151 déc. 2015Covidien LpDetachable buttress material retention systems for use with a surgical stapling device
US91987854 déc. 20131 déc. 2015Abbott Cardiovascular Systems Inc.Crush recoverable polymer scaffolds
US92051505 déc. 20128 déc. 2015Incept, LlcMedical organogel processes and compositions
US923280528 juin 201112 janv. 2016Biocure, Inc.In-situ forming hydrogel wound dressings containing antimicrobial agents
US92378932 mars 201519 janv. 2016Covidien LpSurgical stapling apparatus including buttress attachment via tabs
US924803423 août 20052 févr. 2016Advanced Cardiovascular Systems, Inc.Controlled disintegrating implantable medical devices
US925426711 juil. 20089 févr. 2016Incept, LlcComposite hydrogel drug delivery systems
US925934127 févr. 201316 févr. 2016Abbott Cardiovascular Systems Inc.Methods for improving stent retention on a balloon catheter
US926572330 juil. 201023 févr. 2016Sanofi-Aventis Deutschland GmbhLong acting insulin composition
US92658288 mai 201423 févr. 2016Covidien LpHydrogel implants with varying degrees of crosslinking
US926585817 oct. 201423 févr. 2016Ferrosan Medical Devices A/SDry haemostatic composition
US927170620 oct. 20091 mars 2016Covidien LpMedical device for wound closure and method of use
US92779222 mars 20158 mars 2016Covidien LpSurgical stapling apparatus including buttress attachment via tabs
US928309925 août 200415 mars 2016Advanced Cardiovascular Systems, Inc.Stent-catheter assembly with a releasable connection for stent retention
US928944923 juil. 201422 mars 2016Spotlight Technology Partners LlcHydrogel compositions
US929557023 févr. 200529 mars 2016Abbott Laboratories Vascular Enterprises LimitedCold-molding process for loading a stent onto a stent delivery system
US9308169 *2 mai 201212 avr. 2016Biosphere Medical, Inc.Microspheres for active embolization
US930828321 août 201412 avr. 2016Incept, LlcImplants and biodegradable fiducial markers
US93269341 mai 20123 mai 2016Angiotech International AgDrug delivery from rapid gelling polymer composition
US9327030 *5 sept. 20143 mai 2016Warsaw Orthopedic, Inc.Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US935321814 juin 201331 mai 2016Angiotech Pharmaceuticals, Inc.Kit for multifunctional compounds forming crosslinked biomaterials
US935832522 avr. 20157 juin 2016Abbott Cardiovascular Systems Inc.Stents with radiopaque markers
US936423425 mars 201514 juin 2016Covidien LpInterlocking buttress material retention system
US937048527 août 201421 juin 2016Incept, LlcHydrogel polymeric compositions and methods
US937060121 août 201421 juin 2016Actamax Surgical Materials, LlcDextran-based polymer tissue adhesive for medical use
US937060812 déc. 201421 juin 2016RTI Surgical Inc.Continuous matrix with osteoconductive particles dispersed therein, method of forming thereof, and method of regenerating bone therewith
US937550519 févr. 201428 juin 2016Baxter International Inc.Hemostatic sponge
US938099820 févr. 20145 juil. 2016Devicor Medical Products, Inc.Subcutaneous cavity marking device and method
US9393100 *16 nov. 201119 juil. 2016Endologix, Inc.Devices and methods to treat vascular dissections
US939334411 janv. 200719 juil. 2016Hyperbranch Medical Technology, Inc.Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US9399076 *17 mai 200526 juil. 2016Medtronic Minimed, Inc.Optical sensor for in vivo detection of analyte
US94026231 juil. 20142 août 2016Covidien LpSurgical fasteners
US94089451 juin 20119 août 2016Baxter International Inc.Process for making dry and stable hemostatic compositions
US943963615 sept. 201413 sept. 2016Covidien LpWound plugs
US944579516 mars 201020 sept. 2016Confluent Surgical, Inc.Prevention of premature gelling of delivery devices for pH dependent forming materials
US945706614 mai 20154 oct. 2016Sanofi-Aventis Deutschland GmbhProdrugs comprising an insulin linker conjugate
US94630044 mai 201011 oct. 2016Incept, Llc.Biomaterials for track and puncture closure
US946342624 juin 200511 oct. 2016Boston Scientific Scimed, Inc.Methods and systems for coating particles
US94686845 févr. 201518 oct. 2016Covidien LpHydrogel implants with varying degrees of crosslinking
US948175219 juin 20071 nov. 2016Boston Scientific Scimed, Inc.Polymeric particles comprising vinyl formal, vinyl alcohol and vinyl acetate monomer units
US948621515 janv. 20158 nov. 2016Covidien LpSurgical stapling apparatus
US949257011 mai 201015 nov. 2016Devicor Medical Products, Inc.Device and method for safe location and marking of a biopsy cavity
US951720322 mai 201213 déc. 2016Mediv As, LlcPolymer particle delivery compositions and methods of use
US951728730 juin 201413 déc. 2016Baxter International, Inc.Hemostatic sponge
US952296328 juin 201220 déc. 2016Covidien LpDissolution of oxidized cellulose
US953288831 déc. 20143 janv. 2017Abbott Cardiovascular Systems Inc.Stents with radiopaque markers
US953306920 déc. 20133 janv. 2017Ferrosan Medical Devices A/SDevice for promotion of hemostasis and/or wound healing
US95612471 nov. 20127 févr. 2017Tif Management, LlcMethods and compositions for wound treatment
US957910330 avr. 201028 févr. 2017Endologix, Inc.Percutaneous method and device to treat dissections
US957922524 nov. 201428 févr. 2017Abbott Cardiovascular Systems Inc.Methods for improving stent retention on a balloon catheter
US959229914 mars 201614 mars 2017Spotlight Technology Partners LlcHydrogel compositions
US95970777 janv. 201621 mars 2017Covidien LpButtress attachment to the cartridge surface
US962275325 sept. 201418 avr. 2017Microvention, Inc.Aneurysm treatment device and method of use
US962314630 janv. 201518 avr. 2017RTI Surgical Technology, Inc.Bone implant materials comprising cross-linked bioactive hydrogel matrices
US96637654 sept. 201530 mai 2017Vbi Technologies, L.L.C.Subpopulations of spore-like cells and uses thereof
US966911323 déc. 19996 juin 2017Devicor Medical Products, Inc.Device and method for safe location and marking of a biopsy cavity
US966911710 mars 20166 juin 2017Incept, LlcImplants and biodegradable tissue markers
US968745026 févr. 201627 juin 2017Covidien LpOxidized cellulose microspheres
US968757312 mars 201427 juin 2017Biosphere Medical, Inc.Compositions and associated methods for radioisotope-binding microparticles
US969411610 mai 20164 juil. 2017Abbott Cardiovascular Systems Inc.Stents with radiopaque markers
US97006505 nov. 201011 juil. 2017Spotlight Technology Partners LlcPolysaccharide based hydrogels
US97072529 févr. 200618 juil. 2017Covidien LpSynthetic sealants
US970731526 août 201518 juil. 2017Covidien LpHydrogel implants with varying degrees of crosslinking
US972407820 juin 20148 août 2017Ferrosan Medical Devices A/SVacuum expanded dry composition and syringe for retaining same
US20010034528 *2 févr. 200125 oct. 2001Foerster Seth A.Methods and devices for defining and marking tissue
US20010056301 *13 mars 200127 déc. 2001Goupil Dennis W.Hydrogel biomedical articles
US20020026201 *18 sept. 200128 févr. 2002Foerster Seth A.Methods for defining and marking tissue
US20020035324 *13 mars 200121 mars 2002Sirimanne D. LaksenSubcutaneous cavity marking device and method
US20020058882 *30 nov. 200116 mai 2002Artemis Medical, IncorporatedBiopsy localization method and device
US20020107437 *1 avr. 20028 août 2002Sirimanne D. LaksenSubcutaneous cavity marking device and method
US20020114775 *5 févr. 200222 août 2002Incept LlcCrosslinking agents and methods of use
US20020133225 *22 févr. 200219 sept. 2002Gordon Lucas S.Methods and apparatuses for delivering a medical agent to a medical implant
US20020187172 *5 sept. 200112 déc. 2002Philippe RebColloidal metal labeled microparticles and methods for producing and using the same
US20020193815 *7 août 200219 déc. 2002Foerster Seth A.Methods and devices for defining and marking tissue
US20030007991 *3 août 20019 janv. 2003Masters David B.Devices including protein matrix materials and methods of making and using thereof
US20030018294 *20 juil. 200123 janv. 2003Cox Brian J.Aneurysm treatment device and method of use
US20030077242 *8 oct. 200224 avr. 2003Incept LlcMethods for forming regional tissue adherent barriers and drug delivery systems
US20030097173 *10 janv. 200322 mai 2003Debashis DuttaBiodegradable drug delivery material for stent
US20030100921 *8 mai 200229 mai 2003Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US20030100942 *2 oct. 200229 mai 2003Ken Christopher G. M.Hydrogel for the therapeutic treatment of aneurysms
US20030105518 *10 janv. 20035 juin 2003Debashis DuttaBiodegradable drug delivery material for stent
US20030108511 *13 déc. 200212 juin 2003Sawhney Amarpreet S.Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US20030119985 *30 sept. 200226 juin 2003Sehl Louis C.Methods for tissue repair using adhesive materials
US20030162841 *25 févr. 200328 août 2003InceptBiocompatible crosslinked polymers
US20030183966 *6 août 20022 oct. 2003Lixiao WangMethod of manufacture medical devices employing microwave energy
US20030183972 *17 janv. 20032 oct. 2003Jan WeberMethod and apparatus for extruding polymers employing microwave energy
US20030211073 *19 juin 200313 nov. 2003Goupil Dennis W.Tissue bulking and coating compositions
US20030211165 *23 mars 200113 nov. 2003Jean-Marie VogelMicrospheres for active embolization
US20030215519 *14 mars 200320 nov. 2003Alexander SchwarzEmbolization using degradable crosslinked hydrogels
US20030229333 *24 févr. 200311 déc. 2003Control Delivery Systems, Inc.Methods for treating otic disorders
US20030232746 *21 févr. 200318 déc. 2003Encelle, Inc.Cross-linked bioactive hydrogel matrices
US20040002456 *11 févr. 20031 janv. 2004Incept LlcMethods and devices for preparing protein concentrates
US20040009205 *9 juil. 200315 janv. 2004Incept LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US20040021249 *28 mars 20035 févr. 2004Jan WeberPolymer welding using ferromagnetic particles
US20040024304 *30 juil. 20035 févr. 2004Foerster Seth A.Methods and devices for defining and marking tissue
US20040033598 *3 mars 200319 févr. 2004University Of Massachusetts, A Massachusetts CorporationCompositions and methods for generating skin
US20040049187 *22 oct. 200111 mars 2004Stuart BurnettSelf-adhesive hydratable matrix for topical therapeutic use
US20040063613 *30 sept. 20031 avr. 2004James RolkeMethods and compositions for sealing tissue leaks
US20040072756 *30 sept. 200315 avr. 2004James WilkiePrimers for use with tissue sealants and adhesives and methods for using the same
US20040101564 *29 août 200327 mai 2004Rioux Robert F.Embolization
US20040122165 *12 déc. 200324 juin 2004Chee-Youb WonHydrogel-forming system with hydrophobic and hydrophilic components
US20040143180 *9 janv. 200422 juil. 2004Sheng-Ping ZhongMedical devices visible under magnetic resonance imaging
US20040151752 *23 janv. 20045 août 2004Chee-Youb WonHydrogel entrapping therapeutic agent and stent with coating comprising this
US20040153025 *3 févr. 20035 août 2004Seifert Paul S.Systems and methods of de-endothelialization
US20040170685 *26 févr. 20042 sept. 2004Medivas, LlcBioactive stents and methods for use thereof
US20040185084 *27 janv. 200423 sept. 2004Rhee Woonza M.Synthetic implant with nonimmunogenicity coating
US20040186230 *27 janv. 200423 sept. 2004Rhee Woonza M.Composition for administration of a biologically active compound
US20040186231 *27 janv. 200423 sept. 2004Rhee Woonza M.Dehydrated, shaped matrix and use thereof in the treatment of vascular malformation
US20040193039 *27 mars 200330 sept. 2004Jan WeberMedical device with temperature modulator for use in magnetic resonance imaging
US20040204660 *4 mai 200414 oct. 2004Artemis Medical, Inc.Biopsy localization method and device
US20040210160 *4 mai 200421 oct. 2004Fulton Richard E.Biopsy localization method and device
US20040215231 *5 févr. 200128 oct. 2004David FortuneDevice for the closure of a surgical puncture
US20040219214 *30 déc. 20034 nov. 2004Angiotech International AgTissue reactive compounds and compositions and uses thereof
US20040235708 *27 janv. 200425 nov. 2004Rhee Woonza M.Method for preventing the formation of adhesions following surgery or injury
US20040253203 *11 juin 200316 déc. 2004Hossainy Syed F.A.Bioabsorbable, biobeneficial polyester polymers for use in drug eluting stent coatings
US20040267155 *25 juil. 200330 déc. 2004Fulton Richard EustisBiopsy localization method and device
US20050008610 *5 mars 200413 janv. 2005Alexander SchwarzTemporary embolization using inverse thermosensitive polymers
US20050027070 *13 août 20043 févr. 2005Rhee Woonza M.Method for preparing a biocompatible crosslinked matrix and matrix provided thereby
US20050033349 *23 juin 200410 févr. 2005Jones Donald K.Stent aneurysm embolization device
US20050033408 *23 juin 200410 févr. 2005Jones Donald K.Stent embolization device
US20050036946 *9 août 200417 févr. 2005Pathak Chandrashekhar P.Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US20050037960 *30 sept. 200317 févr. 2005James RolkeMethods and compositions for sealing tissue leaks
US20050054771 *22 oct. 200410 mars 2005Sehl Louis C.Adhesive tissue repair patch
US20050059888 *6 oct. 200417 mars 2005Sirimanne D. LaksenBiopsy cavity marking device and method
US20050079999 *30 sept. 200314 avr. 2005James WilkieMethods for controlling the viscosity of polymer-based tissue sealants and adhesives
US20050080337 *7 oct. 200414 avr. 2005Vivant Medical, Inc.Biopsy site marker
US20050080338 *8 oct. 200414 avr. 2005Sirimanne D. LaksenBiopsy cavity marking device and method
US20050080339 *8 oct. 200414 avr. 2005Vivant Medical, Inc.Biopsy cavity marking device
US20050085724 *6 oct. 200421 avr. 2005Vivant Medical, Inc.Biopsy cavity marking device and method
US20050085858 *22 oct. 200421 avr. 2005Neomend, Inc.Systems, methods, and compositions for achieving closure of vascular puncture sites
US20050095428 *2 mars 20045 mai 2005Dicarlo PaulEmbolic compositions
US20050124062 *2 déc. 20029 juin 2005UNIVERSITé LAVALMilk protein biofilm and uses thereof
US20050129734 *19 janv. 200516 juin 2005Cornell Research Foundation, Inc.Hydrogel entrapping therapeutic agent and stent with coating comprising this
US20050129775 *27 août 200416 juin 2005Scimed Life Systems, Inc.Ferromagnetic particles and methods
US20050159544 *10 mars 200521 juil. 2005Rhee Woonza M.Crosslinked polymer compositions
US20050214339 *29 mars 200429 sept. 2005Yiwen TangBiologically degradable compositions for medical applications
US20050214492 *25 mars 200429 sept. 2005Shen-Ping ZhongThermoplastic medical device
US20050232971 *16 juin 200520 oct. 2005Hossainy Syed FBiodegradable polymers for use with implantable medical devices
US20050266086 *1 juin 20041 déc. 2005Sawhney Amarpreet SIntrauterine applications of materials formed in situ
US20050287218 *29 juin 200529 déc. 2005Hassan ChaoukBiomaterial
US20050288789 *29 juin 200529 déc. 2005Hassan ChaoukSpinal disc nucleus pulposus implant
US20060015170 *16 juil. 200419 janv. 2006Jones Ryan AContrast coated stent and method of fabrication
US20060024357 *12 mai 20052 févr. 2006Medivas, LlcWound healing polymer compositions and methods for use thereof
US20060024371 *2 déc. 20042 févr. 2006Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US20060036159 *30 sept. 200516 févr. 2006Sirimanne D LBiopsy cavity marking device
US20060036211 *29 juil. 200516 févr. 2006X-Sten, Inc.Spinal ligament modification kit
US20060067883 *19 juil. 200530 mars 2006Biosphere Medical, Inc.Microspheres capable of binding radioisotopes, optionally comprising metallic microparticles, and methods of use thereof
US20060069063 *27 sept. 200430 mars 2006Yng-Jiin WangCrosslinked polygalacturonic acid used for postsurgical tissue adhesion prevention
US20060073101 *24 sept. 20036 avr. 2006Oldfield Edward HMethod for convection enhanced delivery of therapeutic agents
US20060078536 *6 oct. 200513 avr. 2006Kodokian George KPolysaccharide-based polymer tissue adhesive for medical use
US20060079599 *5 oct. 200513 avr. 2006Arthur Samuel DPolymer-based tissue-adhesive form medical use
US20060079770 *18 nov. 200513 avr. 2006Sirimanne D LBiopsy site marker
US20060079829 *18 nov. 200513 avr. 2006Fulton Richard EBiopsy localization method and device
US20060093648 *12 déc. 20054 mai 2006Genzyme CorporationHydrogels for orthopedic repair
US20060104969 *16 août 200518 mai 2006Massachusetts Institute Of TechnologyCompositions and methods for enhancing structural and functional nervous system reorganization and recovery
US20060105026 *2 avr. 200418 mai 2006Fortune David HTissue-adhesive formulations
US20060147409 *2 déc. 20056 juil. 2006Incept LlcBiocompatible crosslinked polymers with visualization agents
US20060167561 *1 déc. 200527 juil. 2006Johann OdarMethods for repairing and regenerating human dura mater
US20060188486 *1 févr. 200624 août 2006Medivas, LlcWound care polymer compositions and methods for use thereof
US20060193899 *19 avr. 200631 août 2006Incept LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US20060263301 *26 avr. 200423 nov. 2006Brent VernonIn situ gelling self-reactive materials for embolization
US20060292690 *21 juin 200628 déc. 2006Cesco Bioengineering Co., Ltd.Method of making cell growth surface
US20070048251 *24 août 20061 mars 2007Arthur Samuel DMethods for sealing an orifice in tissue using an aldol-crosslinked polymeric hydrogel adhesive
US20070048337 *24 août 20061 mars 2007Arthur Samuel DAldol-crosslinked polymeric hydrogel adhesives
US20070065483 *11 nov. 200522 mars 2007Chudzik Stephen JIn vivo formed matrices including natural biodegradable polysaccharides and uses thereof
US20070065484 *21 sept. 200622 mars 2007Chudzik Stephen JIn situ occlusion using natural biodegradable polysaccharides
US20070077272 *21 sept. 20065 avr. 2007Medivas, LlcSolid polymer delivery compositions and methods for use thereof
US20070102848 *27 nov. 200610 mai 2007Boston Scientific Scimed, Inc.Apparatus for Extruding Polymers Employing Microwave Energy
US20070123689 *20 déc. 200631 mai 2007Advanced Cardiovascular Systems, Inc.Bioabsorbable, biobeneficial polyester polymers for stent coatings
US20070123890 *2 nov. 200631 mai 2007X-Sten, Corp.Tissue retrieval devices and methods
US20070135566 *8 déc. 200614 juin 2007Tyco Healthcare Group LpViscosity-reduced sprayable compositions
US20070135605 *8 déc. 200614 juin 2007Tyco Healthcare Group LpBiocompatible surgical compositions
US20070149641 *28 déc. 200528 juin 2007Goupil Dennis WInjectable bone cement
US20070160622 *7 déc. 200612 juil. 2007Medivas, LlcMethod for assembling a polymer-biologic delivery composition
US20070167735 *12 déc. 200619 juil. 2007Sheng-Ping ZhongImplantable or insertable medical devices visible under magnetic resonance imaging
US20070196454 *11 janv. 200723 août 2007Hyperbranch Medical Technology, Inc.Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices
US20070197776 *20 mars 200723 août 2007Incept LlcHydrogels for protein concentration
US20070231366 *18 août 20064 oct. 2007Sawhney Amarpreet SSuperabsorbent, freeze dried hydrogels for medical applications
US20070254005 *24 août 20051 nov. 2007Pathak Chandraskekhar PImplantable Tissue Compositions and Method
US20070280851 *15 mai 20076 déc. 2007Abigail FreemanRadiation sterilization of medical devices
US20070282011 *9 mai 20076 déc. 2007Medivas, LlcBiodegradable water soluble polymers
US20070282366 *30 mai 20066 déc. 2007Farhad KhosraviMaterials formable in situ within a medical device
US20070286891 *29 juil. 200513 déc. 2007Tissuemed LimitedTissue-Adhesive Materials
US20070288052 *13 avr. 200713 déc. 2007Incept LlcIn situ materials formation
US20070292476 *1 mai 200720 déc. 2007Medivas, LlcDelivery of ophthalmologic agents to the exterior or interior of the eye
US20070299459 *26 juin 200627 déc. 2007X-Sten Corp.Percutaneous Tissue Access Device
US20080017201 *8 août 200724 janv. 2008Incept LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US20080038313 *9 oct. 200714 févr. 2008Neomend, Inc.Systems, methods, and compositions for mixing and applying lyophilized biomaterials
US20080077179 *21 nov. 200727 mars 2008Neomend, Inc.Pretreatment method for enhancing tissue adhesion
US20080103583 *2 janv. 20081 mai 2008Debashis DuttaBiodegradable drug delivery material for stent
US20080108577 *21 déc. 20078 mai 2008Neomend, Inc.Tissue adhering compositions
US20080114092 *14 janv. 200815 mai 2008Incept LlcAdhesion barriers applicable by minimally invasive surgery and methods of use thereof
US20080131510 *16 nov. 20075 juin 2008Gemeinhart Richard AComposition and method for providing localized delivery of a therapeutic agent
US20080132936 *21 déc. 20075 juin 2008Incept LlcIn situ materials formation
US20080140114 *13 févr. 200812 juin 2008Neomend, Inc.Systems and methods for sealing a vascular puncture
US20080154241 *7 déc. 200726 juin 2008Burkstrand Michael JLatent stabilization of bioactive agents releasable from implantable medical articles
US20080175817 *23 juil. 200724 juil. 2008Neomend, Inc.Biocompatible material composition adaptable to diverse therapeutic indications
US20080187568 *6 févr. 20087 août 2008Sawhney Amarpreet SPolymerization with precipitation of proteins for elution in physiological solution
US20080187591 *1 août 20077 août 2008Baxter International, Inc.Rapidly acting dry sealant and methods for use and manufacture
US20080207794 *30 août 200728 août 20083M Innovative Properties CompanyPolymeric fibers and methods of making
US20080214695 *13 févr. 20084 sept. 2008Pathak Chandrashekhar PBiocompatible crosslinked polymers with visualization agents
US20080220077 *16 mai 200811 sept. 2008Biosphere Medical, Inc.Microspheres for active embolization
US20080221383 *12 févr. 200811 sept. 2008Vertos Medical, Inc.Tissue excision devices and methods
US20080227944 *28 déc. 200518 sept. 2008Luigi AmbrosioBiodegradable, Super Absorbent Polymer Hydrogels and a Method For Their Preparation
US20080253987 *14 avr. 200816 oct. 2008Kuros Biosurgery AgPolymeric tissue sealant
US20080260802 *29 mai 200823 oct. 2008Sawhney Amarpreet SBiocompatible hydrogels made with small molecule precursors
US20080267902 *27 avr. 200730 oct. 2008Hillary EnyartBlood products with binding agent
US20080268058 *19 juin 200730 oct. 2008Boston Scientific Scimed, Inc.Particles
US20080279898 *29 juil. 200813 nov. 2008Advanced Cardiovascular Systems Inc.Biologically Degradable Compositions For Medical Applications
US20080286376 *21 juil. 200820 nov. 2008Fusion Medical Technologies, Inc.Dry hemostatic compositions and methods for their preparation
US20080287633 *18 mai 200720 nov. 2008Drumheller Paul DHydrogel Materials
US20080299339 *5 mai 20084 déc. 2008Personics Holdings Inc.Earguard sealing system i: multi-chamber systems
US20080300339 *7 juin 20074 déc. 20083M Innovative Properties CompanyPolymeric beads and methods of making polymeric beads
US20080311324 *5 mai 200818 déc. 2008Personics Holdings Inc.Earguard sealing system ii: single-chamber systems
US20090018575 *1 mars 200715 janv. 2009Tissuemed LimitedTissue-adhesive formulations
US20090029937 *22 juil. 200829 janv. 2009Cornell UniversityBiodegradable cationic polymer gene transfer compositions and methods of use
US20090030117 *23 sept. 200829 janv. 2009Boston Scientific Scimed, Inc.Porous polymeric particle comprising polyvinyl alcohol and having interior to surface porosity-gradient
US20090030451 *9 févr. 200529 janv. 2009Hadba Ahmad RSynthetic Sealants
US20090035249 *28 juil. 20085 févr. 2009Bhatia Sujata KMethod of inhibiting proliferation of Escherichia coli
US20090035352 *23 sept. 20085 févr. 2009Boston Scientific Scimed, Inc.Drug Delivery Particle
US20090036936 *8 août 20085 févr. 2009Vertos Medical, Inc.Translaminar approach to minimally invasive ligament decompression procedure
US20090047349 *1 juil. 200819 févr. 2009Confluent Surgical, Inc.Drug delivery device
US20090054535 *20 août 200826 févr. 2009Figuly Garret DMethod for embolization using liquid embolic materials
US20090082853 *1 déc. 200826 mars 2009Advanced Cardiovascular Systems Inc.Biodegradable drug delivery material for stent
US20090088723 *3 juil. 20082 avr. 2009Accessclosure, Inc.Apparatus and methods for treating pseudoaneurysms
US20090118709 *29 oct. 20087 mai 2009Vertos Medical, Inc. A Delaware CorporationTissue Excision Tool, Kits and Methods of Using the Same
US20090130162 *24 août 200521 mai 2009Chandraskekhar PathakImplantable tissue compositions and method
US20090130423 *10 nov. 200821 mai 2009Personics Holdings Inc.Electroactive polymer systems
US20090155518 *9 déc. 200818 juin 2009Personics Holdings Inc.Energy responsive conformal device
US20090192214 *28 oct. 200830 juil. 2009Angiotech International AgDrug delivery from rapid gelling polymer composition
US20090198177 *4 févr. 20086 août 2009Sawhney Amarpreet SSurgical delivery system for medical sealant
US20090202642 *9 févr. 200913 août 2009Xiao HuangDrug Delivery System Comprising Microparticles and Gelation System
US20090209658 *23 avr. 200920 août 2009Goupil Dennis WEmbolic compositions
US20090221891 *17 mai 20053 sept. 2009Yihua YuOptical sensor for in vivo detection of analyte
US20090227689 *27 mars 200910 sept. 2009Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090227779 *19 mai 200910 sept. 2009Baxter International, Inc.Dry hemostatic compositions and methods for their preparation
US20090227981 *27 mars 200910 sept. 2009Bennett Steven LLow-Swelling Biocompatible Hydrogels
US20090252781 *16 juin 20098 oct. 2009Incept LlcHydrogel polymeric compositions and methods
US20090280181 *7 mai 200912 nov. 2009Joram SlagerDelivery of nucleic acid complexes from particles
US20090287297 *28 juil. 200919 nov. 2009Cox Brian JAneurysm Treatment Device And Method Of Use
US20090324721 *1 juil. 200931 déc. 2009Jack KennedyHydrogels Suitable For Use In Polyp Removal
US20100009440 *17 juil. 200914 janv. 2010Vbi Technologies, L.L.C.Spore-like cells and uses thereof
US20100015231 *6 juil. 200921 janv. 2010E.I. Du Pont De Nemours And CompanyLow swell, long-lived hydrogel sealant
US20100028309 *30 mai 20074 févr. 2010Baxter International Inc.Method for directed cell in-growth and controlled tissue regeneration in spinal surgery
US20100029908 *13 oct. 20094 févr. 2010Boston Scientific Scimed, Inc.Absorbable sponge with contrasting agent
US20100040664 *12 août 200918 févr. 2010Medivas, LlcAabb-poly(depsipeptide) biodegradable polymers and methods of use
US20100055153 *3 déc. 20084 mars 2010Transdermal Innovations Inc.Multipurpose hydrogel compositions and products
US20100086678 *27 nov. 20078 avr. 2010E.I.Dupont De Nemours And CompanyBranched end reactants and polymeric hydrogel tissue adhesives therefrom
US20100087854 *20 oct. 20098 avr. 2010Joshua StopekMedical device for wound closure and method of use
US20100109178 *5 janv. 20106 mai 2010Boston Scientific Scimed, Inc.Embolization
US20100119451 *18 janv. 201013 mai 2010Incept, LlcMethods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels
US20100129290 *26 nov. 200827 mai 2010I.S.T. CorporationSmart contrast agent and detection method for detecting transition metal ions
US20100160960 *9 nov. 200924 juin 2010E. I. Du Pont De Nemours And CompanyHydrogel tissue adhesive having increased degradation time
US20100173843 *17 déc. 20098 juil. 2010Neomend, Inc.Tissue adhering compositions
US20100185226 *26 mars 201022 juil. 2010Pluromed, Inc.Internal Clamp for Surgical Procedures
US20100226960 *21 sept. 20069 sept. 2010Surmodics, Inc.Natural biodegradable matrices and uses thereof
US20100227794 *24 mars 20109 sept. 2010I.S.T. CorporationSmart contrast agent and method for detecting transition metal ions and treating related disorders
US20100233246 *25 mai 201016 sept. 2010Angiotech Pharmaceuticals (Us), Inc.Adhesive tissue repair patch and collagen sheets
US20100255101 *14 nov. 20087 oct. 2010E.I.Du Pont De Nemours And CompanyDextran-based polymer tissue adhesive for medical use
US20100256671 *7 avr. 20097 oct. 2010Biomedica Management CorporationTissue sealant for use in noncompressible hemorrhage
US20100272804 *14 nov. 200828 oct. 2010E. I. Du Pont De Nemours And CompanyOxidized cationic polysaccharide-based polymer tissue adhesive for medical use
US20100280546 *4 mai 20104 nov. 2010Patrick CampbellBiomaterials for track and puncture closure
US20100290995 *21 juil. 201018 nov. 2010Pathak Holdings LlcRadio-opaque compounds, compositions containing same and methods of their synthesis and use
US20100292717 *18 mai 200918 nov. 2010Baxter International Inc.Method for the improvement of mesh implant biocompatibility
US20100295219 *8 déc. 200825 nov. 2010Ylitalo Caroline MMethods of making shaped polymeric materials
US20100318048 *16 juin 201016 déc. 2010Baxter International Inc.Hemostatic sponge
US20110027335 *11 août 20083 févr. 2011Tissuemed LimitedCoated medical devices
US20110033515 *4 août 200910 févr. 2011Rst Implanted Cell TechnologyTissue contacting material
US20110033548 *3 août 201010 févr. 2011E.I. Du Pont De Nemours And CompanyDegradable crosslinked aminated dextran microspheres and methods of use
US20110045047 *3 nov. 201024 févr. 2011Confluent Surgical, Inc.Hemostatic implant
US20110045075 *1 juin 200924 févr. 2011E. I. Du Pont De Nemours And CompanyTissue coating for preventing undesired tissue-to-tissue adhesions
US20110045589 *6 oct. 201024 févr. 2011Gamida Cell Ltd.Methods Of Controlling Proliferation And Differentiation Of Stem And Progenitor Cells
US20110076231 *30 avr. 201031 mars 2011Pluromed, Inc.Temporary embolization using inverse thermosensitive polymers
US20110081397 *22 sept. 20107 avr. 2011Tyco Healthcare Group LpMesh Implant
US20110081398 *23 sept. 20107 avr. 2011Tyco Healthcare Group LpMulti-mechanism surgical compositions
US20110081417 *23 sept. 20107 avr. 2011Tyco Healthcare Group LpSurgical compositions
US20110081701 *8 oct. 20107 avr. 2011Timothy SargeantSurgical compositions
US20110082068 *12 juin 20097 avr. 2011Ylitalo Caroline MMethod of making a cleaning solution from hydrogel cleaning concentrate and packaged cleaning concentrate
US20110087271 *4 oct. 201014 avr. 2011Timothy SargeantWound Closure Device
US20110087272 *4 oct. 201014 avr. 2011Timothy SargeantWound Closure Device
US20110087273 *4 oct. 201014 avr. 2011Tyco Healthcare Group LpWound Closure Device
US20110087274 *4 oct. 201014 avr. 2011Tyco Healtcare Group LP, New Haven, CtWound Closure Device
US20110091549 *16 mars 201021 avr. 2011Confluent Surgical, Inc.Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels
US20110092613 *16 déc. 201021 avr. 2011Incept LlcMaterials formable in situ within a medical device
US20110092899 *16 mars 201021 avr. 2011Confluent Surgical, Inc.Prevention Of Premature Gelling Of Delivery Devices For pH Dependent Forming Materials
US20110093057 *16 mars 201021 avr. 2011Confluent Surgical, Inc.Mitigating Thrombus Formation On Medical Devices By Influencing pH Microenvironment Near The Surface
US20110097376 *27 oct. 200928 avr. 2011Spine Wave, Inc.Radiopaque injectable nucleus hydrogel compositions
US20110125185 *28 oct. 201026 mai 2011Tyco Healthcare Group Lp,Wound Plugs
US20110142936 *15 déc. 201016 juin 2011Patrick CampbellImplants and biodegradable fiducial markers
US20110151000 *20 avr. 200923 juin 2011Schultz William JNitric oxide-releasing compositions, devices and methods
US20110159075 *27 déc. 201030 juin 2011Angiodevice International GmbhCompositions and systems for forming crosslinked biomaterials and methods of preparation and use
US20110177150 *29 mars 201121 juil. 2011Pathak Holdings, LlcImplantable tissue compositions and method
US20110195040 *28 déc. 201011 août 2011Angiodevice International GmbhMethod for preventing the formation of adhesions following surgery or injury
US20110202026 *16 déc. 201018 août 2011Baxter International Inc.Hemostatic sponge
US20110224724 *31 août 200915 sept. 2011Lu Helen S MHydrogel tissue adhesive formed from aminated polysaccharide and aldehyde-functionalized multi-arm polyether
US20110251281 *8 sept. 200913 oct. 2011National Institute For Materials ScienceComposite Material Comprising High-Molecular-Weight Matrix and Low-Molecular-Weight Organic Compound and Process For Producing Same
US20120213831 *2 mai 201223 août 2012Biosphere Medical, Inc.Microspheres for active embolization
US20130022548 *14 déc. 201024 janv. 2013Bennett Kevin MMethods and Compositions Relating to Reporter Gels for Use in MRI Techniques
US20130253632 *16 nov. 201126 sept. 2013Endologix, Inc.Devices and methods to treat vascular dissections
US20140328894 *16 juil. 20146 nov. 2014Mati TherapeuticsDrug delivery methods, structures, and compositions for nasolacrimal system
US20140356967 *21 déc. 20124 déc. 2014Hitachi, Ltd.Tissue mimicking phantom and calibration device
US20140377168 *5 sept. 201425 déc. 2014Warsaw Orthopedic, Inc.Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US20160243239 *2 mai 201625 août 2016Warsaw Orthopedic, Inc.Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
USD61025923 oct. 200816 févr. 2010Vertos Medical, Inc.Tissue modification device
USD61114623 oct. 20082 mars 2010Vertos Medical, Inc.Tissue modification device
USD61925223 oct. 20086 juil. 2010Vertos Medical, Inc.Tissue modification device
USD61925323 oct. 20086 juil. 2010Vertos Medical, Inc.Tissue modification device
USD62059316 sept. 200827 juil. 2010Vertos Medical, Inc.Tissue excision device
USD62193923 oct. 200817 août 2010Vertos Medical, Inc.Tissue modification device
USRE381584 nov. 199824 juin 2003Minnesota Mining And Manufacturing CompanyAdhesive sealant composition
USRE3882714 nov. 200211 oct. 20053M Innovative Properties CompanyAdhesive sealant composition
USRE39456 *13 mai 20052 janv. 2007Micro Therapeutics, Inc.Radioactive embolizing compositions
EP1967220A213 févr. 200810 sept. 2008Confluent Surgical Inc.Low-swelling biocompatible hydrogels
EP2050473A16 août 200822 avr. 2009Confluent Surgical Inc.Drug delivery device
EP2233160A226 mars 201029 sept. 2010Confluent Surgical Inc.Low-swelling biocompatible hydrogels
EP2233161A226 mars 201029 sept. 2010Confluent Surgical Inc.Low-swelling biocompatible hydrogels
EP2308379A17 oct. 201013 avr. 2011Tyco Healthcare Group LPWound closure device
EP2308380A17 oct. 201013 avr. 2011Tyco Healthcare Group LPWound closure device
EP2308381A17 oct. 201013 avr. 2011Tyco Healthcare Group LPWound closure device
EP2308382A17 oct. 201013 avr. 2011Tyco Healthcare Group LPWound closure device
EP2311376A115 oct. 201020 avr. 2011Confluent Surgical Inc.Prevention of premature gelling of delivery devices for pH dependent forming materials
EP2314225A119 oct. 201027 avr. 2011Tyco Healthcare Group LPMedical device for wound closure
EP2314325A230 sept. 201027 avr. 2011Tyco Healthcare Group LPMulti-mechanism surgical compositons
EP2314326A21 oct. 201027 avr. 2011Tyco Healthcare Group LPSurgical compositions
EP2324774A123 nov. 201025 mai 2011Tyco Healthcare Group LPWound plugs
EP2386290A215 mars 201116 nov. 2011Confluent Surgical Inc.Modulating drug release rate by controlling the kinetics of the pH transition in hydrogels
EP2389894A227 mai 201130 nov. 2011Tyco Healthcare Group LPHydrogel implants with varying degrees of crosslinking
EP2389895A227 mai 201130 nov. 2011Tyco Healthcare Group LPHydrogel implants with varying degrees of crosslinking
EP2389896A227 mai 201130 nov. 2011Tyco Healthcare Group LPHydrogel implants with varying degrees of crosslinking
EP2389925A227 mai 201130 nov. 2011Tyco Healthcare Group LPHydrogel implant with varying degrees of crosslinking
EP2389926A227 mai 201130 nov. 2011Tyco Healthcare Group LPHydrogel implants with varying degrees of crosslinking
EP2397164A113 févr. 200821 déc. 2011Confluent Surgical Inc.Low-swelling biocompatible hydrogels
EP2457599A29 sept. 201130 mai 2012Tyco Healthcare Group LPSurgical compositions
EP2468255A220 déc. 201127 juin 2012Confluent Surgical, Inc.Biodegradable osmotic pump implant for drug delivery
EP2474305A26 janv. 201211 juil. 2012Confluent Surgical, Inc.Drug Delivery Implants, Systems and Methods for Making
EP2708226A116 sept. 201319 mars 2014Covidien LPMulti-Encapsulated Formulations Made With Oxidized Cellulose
EP2708227A116 sept. 201319 mars 2014Covidien LPMulti-Encapsulated Formulations Made With Oxidized Cellulose For In-Situ Reactions
EP2759265A219 oct. 201030 juil. 2014Covidien LPMedical device for wound closure
EP2759266A224 janv. 201430 juil. 2014Covidien LPHydrogel filled barbed suture
EP2815771A117 juin 201424 déc. 2014Covidien LPAdhesive barbed filament
EP3031446A127 mai 201115 juin 2016Covidien LPHydrogel implants with varying degrees of crosslinking
EP3085396A122 avr. 201626 oct. 2016Covidien LPResorbable oxidized cellulose embolization solution
WO1996041236A1 *7 juin 199619 déc. 1996The Regents Of The University Of CaliforniaTherapeutic microdevices and methods of making and using same
WO1999009912A113 août 19984 mars 1999Technion Research And Development Foundation Ltd.Intravascular apparatus and method
WO1999022774A1 *21 oct. 199814 mai 1999Micro Therapeutics, Inc.Radioactive embolizing compositions
WO1999022775A1 *3 nov. 199814 mai 1999Micro Therapeutics, Inc.Methods for treating prostate tumors using radioactive compositions
WO2000033764A1 *3 déc. 199915 juin 2000Pathak Chandrashekhar PBiocompatible crosslinked polymers
WO2001028918A1 *3 oct. 200026 avr. 2001Cornell Research Foundation, Inc.Controlled release of doxorubicin
WO2001074928A1 *4 avr. 200111 oct. 2001Bioartificial Gel Technologies Inc.Process for the preparation of protein-based hydrogels
WO2001079315A1 *18 avr. 200125 oct. 2001Clemson UniversityPolylactide/dextran graft co-polymers for biomaterial and tissue engineering applications
WO2003045459A1 *2 déc. 20025 juin 2003UNIVERSITé LAVALMilk protein biofilm and uses thereof
WO2003094930A1 *7 mai 200320 nov. 2003Biosphere Medical, Inc.Embolization using degradable crosslinked hydrogels
WO2005065724A1 *29 déc. 200421 juil. 2005Alnis Biosciences, Inc.Formulations of paramagnetic ion complexes
WO2005070471A2 *20 janv. 20054 août 2005Alnis Biosciences, Inc.Articles comprising magnetic material and bioactive agents
WO2005070471A3 *20 janv. 200530 mars 2006Alnis Biosciences IncArticles comprising magnetic material and bioactive agents
WO2005112587A3 *12 mai 20059 avr. 2009Medivas LlcWound healing polymer compositions and methods for use thereof
WO2008143957A2 *15 mai 200827 nov. 2008Gore Enterprise Holdings, Inc.Hydrogel materials
WO2008143957A3 *15 mai 20088 janv. 2009Paul D DrumhellerHydrogel materials
WO2010067378A28 déc. 200917 juin 2010Reliance Life Sciences Pvt. Ltd.Hydrogel composition
WO2011051406A128 oct. 20105 mai 2011Ascendis Pharma AsSterilization of biodegradable hydrogels
WO2011084465A3 *15 déc. 201017 nov. 2011Incept, LlcImplants and biodegradable fiducial markers
WO2011119340A1 *10 mars 201129 sept. 2011I.S.T. CorporationSmart contrast agent and method for detecting transition metal ions and treating related disorders
WO2013013055A119 juil. 201224 janv. 2013Rubigo Therapeutics, Inc.System for drug delivery and monitoring
WO2014039245A1 *20 août 201313 mars 2014The Regents Of The University Of CaliforniaMethod of creating hydrogels through oxime bond formation
Classifications
Classification aux États-Unis424/426, 516/102, 424/484, 516/106, 516/105, 516/103, 424/488, 514/944, 424/9.364, 424/486
Classification internationaleA61K9/16, A61K49/18, A61K47/42
Classification coopérativeA61K49/1803, A61K9/1658, A61K47/42, Y10S514/944
Classification européenneA61K49/18F, A61K9/16H6H, A61K47/42
Événements juridiques
DateCodeÉvénementDescription
7 août 1992ASAssignment
Owner name: GENERAL HOSPITAL CORPORATION, THE, MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:WEISSLEDER, RALPH;BOGDANOV, ALEXEI;REEL/FRAME:006224/0409
Effective date: 19920807
10 sept. 1996CCCertificate of correction
30 nov. 1999REMIMaintenance fee reminder mailed
18 janv. 2000FPAYFee payment
Year of fee payment: 4
18 janv. 2000SULPSurcharge for late payment
7 nov. 2003FPAYFee payment
Year of fee payment: 8
12 nov. 2007REMIMaintenance fee reminder mailed
7 mai 2008LAPSLapse for failure to pay maintenance fees
24 juin 2008FPExpired due to failure to pay maintenance fee
Effective date: 20080507
19 mai 2011ASAssignment
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF
Free format text: CONFIRMATORY LICENSE;ASSIGNOR:MASSACHUSETTS GENERAL HOSPITAL;REEL/FRAME:026307/0717
Effective date: 19940713